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ABSTRACT 
Therapeutic activation of macrophage phagocytosis has the ability to restrain 
tumor growth through phagocytic clearance of tumor cells and activation of the 
adaptive immune response. The objective of this thesis was to evaluate the 
effects of modulating pro- and anti-phagocytic pathways in malignant melanoma. 
We observed that melanoma cells from mice, humans, and dogs displayed an 
unexpected resistance to phagocytosis that could not be fully mitigated by 
blockade of the “don’t eat me” signal CD47 or by chemotherapeutic 
enhancement of known “eat me” signals. In addition, combination doxorubicin 
chemotherapy and CD47 blockade did not consistently promote an anti-tumor 
adaptive immune response. Phagocytosis of melanoma cells was not enhanced 
by inhibition of secretory pathways, and phagocytosis of sensitive lymphoma 
tumor cells was not impaired in the presence of melanoma culture supernatants, 
indicating that soluble factors did not mediate phagocytosis resistance. siRNA 
mediated knockdown of 47 candidate “don’t eat me” signals similarly did not 
enhance melanoma cell phagocytosis, suggesting that these proteins do not 
disable macrophage phagocytosis. We conclude melanoma cells possess a 
mechanism of resistance to phagocytosis. Further investigation will be needed to 
define this mechanism and to develop strategies to overcome melanoma cell 
resistance to the innate immune response. 
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Section 1: Malignant melanoma  
 Malignant melanoma is a lethal form of skin cancer that arises from 
melanocytes, the pigment forming cells of the skin derived from the neural crest 
[2]. Although genetic factors contribute to the risk of melanoma, environmental 
factors, particularly prolonged exposure to UV radiation, are thought to greatly 
influence the development of melanoma in humans. The incidence rate of this 
cancer has risen rapidly over the past 30 years, and melanoma currently 
represents the fifth and sixth most common cancer in men and women, 
respectively [3]. An estimated 87,110 new cases will be diagnosed and 9,730 
people will die from malignant melanoma in 2017 [3]. Although most patients are 
diagnosed with stage I or II disease, one quarter to one third of all patients with 
melanoma will eventually experience recurrence and development of more 
advanced stage disease [4]. Due to its aggressive nature and propensity for 
metastasis, malignant melanoma results in the majority of human skin cancer 
deaths, despite representing less than five percent of skin cancers overall [2]. 
The lethality of this cancer emphasizes the need to further our understanding of 
melanoma cell biology and develop improved treatments for patients with 
advanced disease. 
1.2 Advances in melanoma treatment 
 Five-year overall survival rates for melanoma diagnosed prior to 
metastasis and treated with surgery alone exceed 90% [3]. However, the 
prognosis for patients with metastatic disease remains poor despite recent 
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therapeutic advances, with five-year overall survival rates around 18% [3]. 
Historically, metastatic melanoma was treated with resection of the primary 
tumor, radiation, and chemotherapy. In 1975, the DNA-methylating compound 
dacarbazine became the first chemotherapeutic drug to receive FDA approval for 
the treatment of melanoma [5]. Although this compound induces complete 
responses in only 5% of malignant melanoma patients, it remained the most 
efficacious treatment for this disease for more than 30 years [4,5]. 
Recent advances in tumor biology and immunology have led to the 
development of targeted agents and immunotherapies which have significantly 
improved the overall survival rate of patients with malignant melanoma [4]. 
Genome-wide screens of cancer mutations revealed that 66% of malignant 
melanomas contain a mutation in the BRAF gene, a serine/threonine kinase in 
the MAP kinase pathway [6]. The discovery that 90% of these mutations result in 
a glutamic acid substitution for valine at amino acid 600 (BRAF V600E) led to the 
development of small-molecule BRAF inhibitors, such as vemurafenib and 
dabrafenib [5]. These targeted agents improved overall response rates in 
advanced melanoma from 5% with dacarbazine alone to nearly 50% with 
vemurafenib and extended progression-free survival from 1.6 months to 5.3 
months [5]. Unfortunately, virtually all of the patients who initially respond to the 
therapy develop resistance to BRAF inhibition and demonstrate disease 
progression within 6-8 months [4,5].  
The most promising advances in treatment of malignant melanoma have 
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come from the field of immunotherapy. The immune system’s ability to recognize 
and eliminate tumor cells was postulated more than a century ago [7], but only 
recent breakthroughs in our understanding of tumor immunology have led to the 
development of immunotherapeutic strategies capable of producing sustained 
clinical responses. At the forefront of these therapies are antibodies targeting 
immune-checkpoints. Signaling via checkpoint molecules, such as CTLA-4 and 
PD-1, acts to limit the efficacy of the anti-tumor response by inducing anergy or 
exhaustion in activated T cells [8,9]. Antibodies against CTLA-4, PD-1, and its 
corresponding ligand PD-L1 aim to reactivate tumor-specific T cells and cause a 
robust anti-tumor immune response [8,9]. Melanoma is generally regarded as 
one of the most immunogenic cancers due to a high prevalence of somatic 
mutations [10]; thus, many immunotherapies have been pioneered for the 
treatment of this disease. The use of immune checkpoint inhibitors has 
revolutionized the treatment of advanced melanoma, with overall response rates 
of 11%, 31%, and 59% for CTLA-4 blockade (Ipilimumab), PD-1 blockade 
(Nivolumab), and combination CTLA-4 and PD-1 blockade, respectively [11,12]. 
A subset of malignant melanoma patients experience durable, complete 
remissions lasting several years. However, the fact that more than 40% of 
patients with malignant melanoma do not respond to combination checkpoint 
blockade underscores the need to develop additional therapeutics for the 
treatment of this disease. 
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Section 2: Comparative Oncology 
Throughout the history of cancer research, animal models have played an 
invaluable role in understanding tumor biology and developing new cancer 
therapies. The ideal model system simulates the features of a human primary 
tumor, such as proliferation, invasion, and metastasis, and the tumor 
microenvironment as closely as possible. Due to their distinct advantages and 
disadvantages, each model system can provide unique insights to improve our 
understanding of cancer biology and drive therapeutic development [13,14].  
The majority of cancer research studies to date have relied on inbred 
mouse models of disease [15]. Mouse models are widely used due to the ability 
to control experimental variables, the ability to manipulate the mouse genome, 
and the ability to easily harvest tumors and immune organs for further study. 
While these models offer valuable insight into the mechanism of action and the 
efficacy of a therapeutic agent, they hold several challenges for clinical 
translation. Mouse xenograft models often underestimate the complexity of the 
heterogeneous tumor microenvironment and, because these model require the 
use of immunodeficient mice, they fail to account for the complex interplay 
between human immune cells and cancer cells [15,16]. In addition, specific 
pathogen free (SPF) housing conditions may affect immune system development 
and alter the gut microbiota of mice, which has recently been shown to play a 
role in the efficacy of immunotherapy [17,18]. Finally, the use of young, inbred 
mouse strains fails to represent the older, obese, and genetically heterogeneous 
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population of human cancer patients, and therapies that succeed in young, 
otherwise healthy animals may not be efficacious in older patients with weakened 
immune systems or comorbidities [15,19]. These inherent challenges may 
explain why only 11% of oncology drugs that demonstrate success in preclinical 
mouse models complete the process of approval for use in human patients [15] 
and emphasize the need to develop better preclinical models of human cancer. 
 The study of spontaneous cancers in companion dogs and cats 
represents an attractive translational model for immunotherapy research [15,16]. 
Comparative oncology has the potential to improve the lives of companion 
animals with cancer and to simultaneously inform the design of human clinical 
trials. Client-owned dogs and cats develop spontaneous cancers that harbor 
comparable genetic abnormalities and develop in the presence of similar 
environmental exposures as human cancers. Dogs and cats represent a more 
outbred population than traditional mouse models and are more reflective of the 
heterogeneity seen in the human population. In addition, these animals are 
immunocompetent and allow the study of anti-tumor immune responses and the 
effects of immunotherapy, including long-term efficacy and toxicity, in a realistic 
clinical setting [15,16]. Although murine and canine models have unique 
advantages and disadvantages (summarized in Table 1-1), both models have the 
potential to significantly inform our understanding of multiple human cancers, 
including melanoma, lymphoma, osteosarcoma, and breast cancer, among 
others.  
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Table 1-1: Advantages and disadvantages of animal models of cancer 
Disease model Advantages Disadvantages 
Murine model -Experimental variables 
(housing, environment, diet) 
are easily controlled 
-Inbred mice are genetically 
identical (may increase 
experimental reproducibility) 
-Genome can be easily 
manipulated  
-Tumors and organs can be 
easily harvested for further 
study 
-Controlled environment and 
diet do not accurately reflect 
human life 
-Young, inbred mice do not 
accurately reflect the 
outbred, aging human 
population 
-Xenograft models and 
genetically induced models 
may be less heterogeneous 
than human tumors 
-Xenograft models are 
immunodeficient 
Canine or feline 
model 
-Develop spontaneous 
tumors that may be more 
heterogeneous 
-Immunocompetent 
-Similar environmental 
exposures to humans 
-Outbred compared to 
mouse models 
-Disease presents in animals 
of differing ages and disease 
status, which is reflective of 
the human population 
-Difficult to control for 
confounding variables and to 
standardize treatments 
-Heterogeneous tumors, 
immune responses, and 
genetics may affect 
reproducibility 
-Increased ethical 
regulations and expectation 
for standard of care 
treatment  
-Limited experimental 
reagents 
 
2.2 Murine models of malignant melanoma 
 Mouse models of melanoma have been traditionally used to study tumor 
growth and the interaction of tumor cells with the host immune system. Mouse 
dermal melanocytes reside deeper within the skin and are better protected from 
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UV radiation than human melanocytes. Due to this difference in melanocyte 
localization, mice rarely develop spontaneous, UV-induced melanoma, and if 
spontaneous tumors do develop, they present with unique histopathological 
properties that are dissimilar to the human disease [14,20]. However, a number 
of clinically relevant mouse models of melanoma have been developed using 
tumor engraftment techniques and genetic modification (reviewed in [14]).  
 Tumor xenograft models facilitate the study of human tumor growth in vivo 
and have played a significant role in cancer drug discovery. In this model, human 
melanoma tumors are engrafted into an immunocompromised mouse and 
allowed to directly interact with the host stroma, including lymphatics and blood 
vessels [13,14]. Although orthotopic engraftment is thought to better mimic 
human tumor formation, melanomas are usually engrafted subcutaneously as 
intradermal injection leads to rapid skin ulceration [14].  By engrafting established 
human cell lines grown in similar culture conditions, investigators can better 
control the timing of tumor growth and reduce interexperimental variability. Cell 
lines are readily available, easily engrafted into mice, and can be genetically 
manipulated to study varying aspects of tumor biology. However, many of these 
lines have been grown under non-physiological conditions for years and may no 
longer accurately reflect human primary tumors [14]. To address these concerns, 
patient-derived xenografts (PDXs), consisting of a fresh biopsy sample from a 
patient, may be engrafted. PDXs are thought to maintain more similarities to 
actual patient tumors than cultured cell lines and could more accurately reflect 
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clinical responses [14]. However, PDX models are expensive, time-consuming, 
and technically challenging. One major limitation of all xenograft models is the 
lack of an intact immune system, which prevents the study of the anti-tumor 
immune response or immunotherapeutic efficacy. To overcome this limitation, 
“humanized” mice can be created by implanting human hematopoietic stem cells 
capable of regenerating elements of the human immune system into irradiated 
mice; however, these humanized PDX models remain expensive and a number 
of technical challenges still hinder model development [13,14].  
 Syngeneic transplantation models, in which mouse melanoma cell lines 
are engrafted into immunocompetent mice with similar major histocompatibility 
complex (MHC) haplotypes, retain the advantages of a xenograft system while 
permitting the study of the anti-melanoma immune response. The most widely 
used syngeneic model of melanoma is the B16 cell line, which was derived from 
a chemically induced melanoma in a C57BL/6J mouse [13]. A number of B16 
subclones with varying propensities for proliferation and metastasis were 
established from the primary tumor and permit the study of different aspects of 
melanoma cell behavior. These clones include B16F1, which retains low 
metastatic potential, and B16F10, which retains high metastatic potential [14]. 
Although B16 cells express low levels of MHC Class I, these cells express high 
levels of melanoma epitopes, including gp100 and TRP2, that can be recognized 
by the host immune system. In addition, these cells can be genetically 
manipulated to express specific tumor antigens. The B16 cell line is commonly 
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used to study immunotherapeutic efficacy, and a great number of reports have 
documented an anti-melanoma immune response in this model system [14]. It is 
important to note that murine melanoma cells differ from human melanoma cells 
in several respects, including differences in adhesion molecule expression, 
growth factor production, mechanisms of invasion, and genetic mutations [13,14]. 
For instance, in direct contrast to human tumors, B16 cells do not contain 
activating mutations in the BRAF oncogene and retain wild type PTEN 
expression [14,21]. Despite these differences, B16 cells remain an important tool 
in the study of anti-melanoma immune responses. These cells proliferate rapidly, 
engraft readily into syngeneic mice, can be genetically manipulated, and are 
capable of forming metastases in distant visceral organs [14].   
 While mice rarely develop spontaneous melanoma, a number of 
genetically engineered mouse models (GEMMs) of melanoma have been 
developed. These models utilize transgenic or knockout mice in which a tumor 
oncogene (such as BRAF or NRAS) has been activated or a tumor suppressor 
(such as CDKN2A or PTEN) has been deleted in order to mimic the genetic 
alterations that occur in human melanoma [13]. GEMMs develop spontaneous 
tumors and may predict drug efficacy more accurately than other preclinical 
models [14]. However, several limitations of GEMMs exist. It can be difficult to 
control the timing of tumor growth in GEMMs, and many of the genetic alterations 
used to create GEMMs induce tumor development in several tissues 
simultaneously, thus limiting the use of the model for studying melanoma [14]. 
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Melanoma in GEMMs may arise in different locations from the human disease 
(such as the CNS) [14]. In addition, many of the melanomas in GEMMs lack the 
radial and vertical growth properties seen in human malignant melanoma, and 
therefore, do not recapitulate human disease progression. Differences in 
melanoma growth could be due to the use of one or two genetic alterations to 
induce melanoma development, which may fail to represent the genetic 
heterogeneity of spontaneous human tumors. Although these tumors develop in 
the presence of an intact immune system, their low mutational burden may fail to 
induce an anti-tumor immune response, and these models are not commonly 
used to study tumor immunology [14,20].  
 While there are many advantages to using mouse models to study 
melanoma, no model can fully recapitulate the complexity of human tumor growth 
or a human tumor microenvironment. Each model system holds unique 
advantages and disadvantages that permit the study of varying aspects of 
melanoma biology. Together, the use of these model systems has led to major 
advances in the diagnosis and treatment of malignant melanoma.  
2.3 Canine malignant melanoma as a model for human disease 
Canine malignant melanoma occurs spontaneously in companion dogs 
and represents another relevant clinical model for human melanoma. Similar to 
the human disease, canine malignant melanoma can present as a highly 
aggressive, metastatic neoplasm. Melanomas represent 3-9% of canine 
neoplasms and 14-45% of canine oral tumors [22]. Unlike human malignant 
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melanoma, canine malignant melanoma typically arises from pigment cells in the 
oral cavity, although it can also be found on the skin, lips, digits, and other 
organs. The pathogenesis of canine melanoma is not fully understood; however, 
the disease distribution suggests that, unlike human melanoma, ultraviolet 
radiation is not a risk factor for disease development [23]. Oral malignant 
melanoma is highly aggressive, with localized invasion present in 57% of tumors, 
and between 70-90% of tumors undergoing metastasis [22,24]. The median 
overall survival for all dogs with malignant melanoma of the oral cavity is 
estimated at less than 150 days [22]. Although oral tumors located at the 
mucocutaneous junction typically display malignant, aggressive behavior, it is 
important to note that oral tumors located on the lips or gums are often benign. 
While less common than oral malignant melanoma, canine acral melanoma 
(found on the foot pads and nail bed) displays a similarly aggressive nature, with 
an estimated 30-40% of cases having metastasized at the time of diagnosis [22]. 
The oral and acral forms of canine malignant melanoma are thought to closely 
mimic the clinical progression of human mucosal and acral melanoma, 
respectively [23]. In contrast to the human forms of the disease, canine 
cutaneous and ocular melanomas are most commonly benign. Most dogs with 
dermal melanoma of haired skin are cured with surgical excision of the tumor, 
with an expectation of almost 90% one-year survival following surgical 
intervention [22].  
Despite differences in the disease distribution and etiology, canine 
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malignant melanoma has been established as a relevant translational model for 
human melanoma and represents a unique opportunity to study the disease in a 
large, immunocompetent animal model [23]. Human and canine malignant 
melanoma share similar clinical presentation, histopathology, and propensity for 
invasion and metastasis (See Table 1-2) [22,25]. At the subcellular level, human 
and canine malignant melanoma share multiple molecular similarities and 
signaling pathways, including activation of the AKT/mTOR pathway, changes in 
KIT signaling, upregulation of COX-2 and CSPG4, and dysregulation of Wnt/b 
catenin signaling [26]. Loss of the tumor suppressor PTEN occurs in 
approximately 20% of human primary tumors and approximately 50% of canine 
tumors [23,27]. In addition, germline mutations in CDKN2, which encodes the 
tumor suppressor p16, are associated with the development of heritable 
melanoma in human families [28,29], and loss of p16 occurs frequently in canine 
melanomas as well [30]. Despite these similarities, some important molecular 
differences exist between human and canine melanoma; in particular, activating 
mutations in BRAF have not been identified in canine melanoma. Although these 
mutations are common in the cutaneous form of human melanoma, BRAF 
mutations are also rare in human mucosal melanoma, emphasizing the 
similarities between the human and canine mucosal forms of the disease [26].     
Similar to human disease, loco-regional control of early stage canine oral 
melanoma can be achieved using radiation or surgery, but few efficacious 
treatments exist for advanced, metastatic disease. Multiple chemotherapy 
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protocols have been described, but response rates following chemotherapy are 
only 8-28%, and there is little evidence that treatment improves overall survival in 
patients with advanced disease [26,31]. Immunotherapies to stimulate the innate 
and adaptive immune system, including cytokine therapy and vaccination, have 
met with varying clinical success [16,26], emphasizing the need to develop new 
therapeutic modalities for the treatment of advanced canine melanoma. 
Table 1-2: Comparison of human malignant melanoma (HMM) and canine 
malignant melanoma (CMM) 
 
Characteristic Similarities Differences 
Clinical 
presentation 
[3,22] 
-Both HMM and CMM can 
found on the skin, mucosa, 
ocular cavity, and digits  
-Middle age to older 
patients 
-Similar appearance: 
raised, usually dark tumors. 
Amelanotic lesions occur 
infrequently 
-HMM is most commonly 
cutaneous 
-CMM is most commonly 
found on the oral mucosa 
Etiology [3,22,26] -Heritable risk and 
inflammation are thought to 
contribute to both HMM 
and CMM  
-UV exposure is a risk 
factor for HMM, but not 
CMM 
Molecular 
signaling 
pathways 
[6,26,32] 
-Both HMM and CMM 
display: activation of the 
AKT/mTOR pathway, 
changes in KIT signaling, 
upregulation of COX-2 and 
CSPG4, dysregulation of 
Wnt/b catenin signaling, 
and loss of PTEN 
-Familiar forms of HMM 
display loss of CDKN2, 
encoding for p16; loss of 
p16 is common in CMM  
-Similar chromosomal 
-BRAF mutations occur in 
66% of cutaneous HMM, 
but are absent in mucosal 
HMM and CMM 
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abnormalities exist 
between mucosal HMM 
and oral CMM, including a 
recurrent pattern of copy 
number gains and losses 
on canine chromosome 30 
and its corresponding 
region on human 
chromosome 15 
Histopathology 
[23] 
-Similar appearance: 3 
major subtypes, epitheloid, 
spindloid, or mixed exist for 
both HMM and CMM 
-Similar structural features 
are utilized for diagnosis 
and staging 
-Several 
immunohistochemical 
markers can be used in the 
evaluation of both human 
and canine melanoma cells 
(melan-A, PNL2, TRP2) 
 
Biological 
behavior [22] 
-HMM and oral CMM 
located at the 
mucocutaneous junction 
display biologically 
aggressive behavior with 
invasion and metastasis 
-Cutaneous canine 
melanoma and oral 
melanoma located on the 
lips or gums are often 
benign 
Treatment 
[5,9,15] 
-Stage I/II CMM and HMM 
are both controlled by 
radiation and surgery  
-Chemotherapy has done 
little to extend survival in 
both CMM and HMM 
-Immunotherapies have 
met with varying success in 
both CMM and HMM; 
evidence of an anti-tumor 
immune response exists in 
both diseases 
-HMM is often treated with 
BRAF inhibitors and 
checkpoint inhibitors 
-Due to the lack of BRAF 
mutations in CMM, BRAF 
inhibitors cannot be 
modeled in dogs and are 
not used therapeutically for 
CMM 
-Reagents for immune 
checkpoint inhibition have 
been developed for dogs, 
but have not undergone 
clinical trials for CMM 
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2.4 Other comparative models of human melanoma 
 In addition to the murine and canine models of malignant melanoma, 
several other animal species can be used to model this disease. Transgenic fish 
models of malignant melanoma have been developed in both zebrafish and 
medaka. Due to the transparency of their embryos, fish models are useful for 
visualizing melanoma development [13]. In addition to mice, nude rats are 
popular xenograft models of human melanoma. Another lab animal used in the 
study of malignant melanoma is the Syrian hamster, which is susceptible to 
spontaneous and chemically induced melanomas. The South American possum 
is highly susceptible to UV radiation-induced melanoma and has been used to 
study the genetics underlying melanoma susceptibility [33]. Miniature Sinclair 
swine develop spontaneous tumors ranging from benign nevi to malignant 
melanomas. Many of these tumors naturally regress subsequent to immune 
activation [34]. Finally, melanocytic tumors commonly occur in horses, 
representing up to 19% of cutaneous equine tumors. UV radiation is not thought 
to be a causative agent in the development of equine melanoma; instead, an 
autosomal dominant mutation resulting in constitutive activation of the ERK 
pathway is thought to contribute to melanoma formation. In contrast to human 
melanoma, many equine melanomas display a prolonged period of benign 
growth, which may or may not progress to malignant transformation and 
metastasis [20]. The study of melanoma in multiple species has led to a greater 
understanding of melanoma genetics, disease progression, and response to drug 
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therapies. However, mouse and canine melanoma remain the most extensively 
utilized models for the study of melanoma-immune system interactions and 
immunotherapeutic efficacy.  
 
Section 3: The role of macrophages in the tumor microenvironment 
 Although the majority of immunotherapies focus on activating the adaptive 
immune system, the innate immune system also has the potential to mediate 
tumor rejection [35,36]. Macrophages are universally found in the tumor 
microenvironment [35] and represent up to 50% of tumor infiltrating leukocytes 
[37]. These cells have the potential to mediate anti-tumor immune responses and 
represent an important immunotherapeutic target [38].  
Two macrophage phenotypes have been described, termed M1 and M2 
[39,40]. Classically activated, or M1, macrophages are thought to act as pro-
inflammatory mediators [37,39]. M1 macrophages have the potential to mediate 
robust anti-tumor immunity through phagocytic clearance of tumor cells, pro-
inflammatory cytokine production, antagonism of myeloid-derived suppressor 
cells (MDSCs) and T regulatory cells, and antigen presentation to the adaptive 
immune system [37,39]. In particular, CD169+ macrophages in the tumor 
microenvironment have been shown to phagocytose and cross-present antigens 
from apoptotic tumor cells.  Cross-presentation, in which exogenous antigens are 
presented on MHC class I molecules, leads to the activation of cytotoxic CD8+ T 
cells and promotes an anti-tumor adaptive immune response [41,42]. A number 
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of cancer therapies rely on the activity of M1 macrophages. For example, 
preclinical models of tumor specific antibodies suggest that cellular Fcg 
receptors, particularly activating receptors on monocytes and macrophages 
(FcgRI, III, and IV in mice and FcgRIa, IIa, and IIIa in humans), are the central 
mediators of antibody activity and tumor depletion in vivo [43]. Antibodies against 
CD47 specifically aim to activate macrophage-mediated phagocytosis of tumor 
cells and will be discussed in detail later in this introduction (Section 3.4) [44].   
In contrast, alternatively activated, or M2 macrophages are thought to 
produce anti-inflammatory cytokines, have poor antigen-presenting capability, 
and inhibit T cell responses. M2 polarized macrophages have been shown to 
promote tumor progression, angiogenesis, and metastasis in a number of cancer 
types, including breast, kidney, and bladder cancer [37]. 
Tumor associated macrophages (TAMs) are often thought to possess a 
cancer-promoting, “M2-like” phenotype. However, the tumor microenvironment is 
extremely heterogeneous, and recent studies have demonstrated that both M1 
and M2 phenotypes are differentially distributed within solid tumor tissues [37]. In 
addition, TAMs may possess mixed phenotypes that display both M1 and M2 
characteristics [40,45]. In these cells, the balance of immunosuppressive and 
inflammatory characteristics can be altered by environmental signals, which 
creates an opportunity to therapeutically bias these cells towards an anti-tumor 
phenotype [45,46].  
There is some evidence that macrophages have the potential to mediate 
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anti-tumor immunity in malignant melanoma. In a preclinical mouse model of 
melanoma, antibody-mediated tumor-cell killing was found to be critically 
dependent on macrophage activity. In this model, CD68+ macrophages 
containing ingested tumor material could be visualized within the tumor 
microenvironment [47]. This study suggests that macrophage-activating 
therapies may be efficacious in the treatment of malignant melanoma.  
3.2 Regulation of phagocytosis: pro-phagocytic signals 
One mechanism by which macrophages mediate anti-tumor immunity is 
through the phagocytosis and direct elimination of tumor cells. Phagocytosis 
relies on a balance of pro-phagocytic (“eat me”) and anti-phagocytic (“don’t eat 
me”) signals expressed on the surface of target cells [48].  Several pro-
phagocytic and anti-phagocytic signals have been identified and will be briefly 
reviewed here. 
Pro-phagocytic signals, such as phosphatidylserine and calreticulin, are 
expressed on the surface of cells undergoing immunogenic cell death. In live 
cells, the phospholipid phosphatidylserine (PS) is asymmetrically distributed to 
the inner leaflet of the plasma membrane [49]. PS exposure on the outer leaflet 
of the membrane is one of the earliest events in apoptosis and occurs prior to the 
loss of membrane integrity [50].  Multiple receptors on the surface of 
macrophages are capable of recognizing PS (such as TIM family receptors and 
BAI1) and facilitating apoptotic cell engulfment. Although PS exposure is known 
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to provide a pro-phagocytic signal, whether this signal alone is sufficient to 
stimulate phagocytic uptake remains a matter of debate [50]. 
Calreticulin (CRT) is an endoplasmic reticulum (ER) chaperone protein 
exposed on the surface of cells during the ER stress response and is often 
expressed on pre-apoptotic cells prior to PS exposure [51]. Many cancer cells 
constitutively express cell surface CRT, which may be a consequence of cellular 
stress in the tumor microenvironment [51,52]. CRT promotes phagocytosis by 
binding to CD91 on the surface of phagocytic cells, including macrophages and 
dendritic cells. In addition, CRT exposure is thought to determine the 
immunogenicity of cancer cell death by promoting the phagocytosis of dying 
cancer cells by CD11c+ dendritic cells, which subsequently present tumor-
associated antigens to anti-tumor T cells and stimulate an anti-tumor immune 
response [51,53]. CRT exposure and immunogenic cell death can be induced by 
treatment with chemotherapy drugs in the anthracycline class, such as 
doxorubicin [53].   
3.3 Regulation of phagocytosis: anti-phagocytic signals 
 Anti-phagocytic, or “don’t eat me,” signals play an important 
physiologically role by inhibiting the phagocytosis of normal somatic cells. The 
best-characterized “don’t eat me” signal is CD47, a cell surface molecule that 
inhibits phagocytosis by binding to SIRPa on the surface of phagocytes [48]. 
CD47 is a member of the immunoglobulin superfamily of membrane proteins and 
contains five membrane spanning segments with a single extracellular 
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immunoglobulin variable domain [54]. CD47’s corresponding receptor, signal-
regulatory protein alpha (SIRPa) [55], is a receptor tyrosine kinase that is highly 
expressed on the surface of myeloid cells, including macrophages, granulocytes, 
monocytes, and myeloid-derived dendritic cells [56]. Ligation of SIRPa’s 
extracellular domain by CD47 results in phosphorylation of an intracellular 
immunoreceptor tyrosine-based inhibitory motif (ITIM) and activation of the 
inhibitory phosphatases SHP-1 and SHP-2 [57]. The resulting signaling cascade 
inhibits the accumulation of myosin within the phagocytic synapse and prevents 
the contractile engulfment of target cells [58].  
 The first evidence that CD47 acts as a “don’t eat me” signal came from 
experiments demonstrating that loss of CD47 leads to the removal of aged or 
damaged red blood cells by splenic macrophages [59]. CD47 has a similar role in 
platelet removal [60], and it has been shown that circulating hematopoietic stem 
cells upregulate CD47 expression to avoid macrophage-mediated clearance [61]. 
Further studies demonstrated that CD47 is ubiquitously expressed on normal 
tissues and acts as a marker of self to prevent cell phagocytosis [48,62].  
Although CD47 was first identified as a tumor antigen on ovarian cancer 
cells [63], it has since been identified on all cancer cells tested, including 
hematopoietic and solid tumors [1,44]. Multiple tumor types display increased 
expression of CD47 compared to their normal cell counterparts, and increased 
expression of CD47 is associated with poor clinical prognosis in acute myeloid 
leukemia (AML), acute lymphoblastic leukemia (ALL), Non-Hodgkin’s lymphoma 
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(NHL), ovarian cancer, and glioblastoma [61,64-66]. Therefore, it is thought that 
CD47 acts as a mechanism of immunoevasion by inhibiting cancer cell 
phagocytosis [1].  
3.4 Therapeutic targeting of the CD47/SIRPa axis 
The identification of CD47 on the surface of human cancer cells and its 
proposed role in immunoevasion led to the development of therapies to inhibit 
the CD47-SIRPa pathway. These therapies include anti-CD47 monoclonal 
antibodies [67], recombinant SIRPa proteins [44], SIRPa mimotopes [68], and 
bispecific molecules targeting CD47 along with a tumor-specific antigen [69,70]. 
The efficacy of CD47 blocking therapies was first examined in a preclinical model 
of AML [64]. Treatment with anti-CD47 antibodies led to macrophage 
phagocytosis of AML cells in vitro and demonstrated anti-tumor effects in 
xenograft models of human AML as well as immunocompetent models of mouse 
AML [64]. Additional studies demonstrated the efficacy of CD47 blockade in a 
number of hematopoietic tumors, including ALL [71], NHL [65], and multiple 
myeloma [72]. Recently, CD47 blockade has been shown to stimulate 
phagocytosis and suppress tumor growth in preclinical models of a number of 
solid tumors, including ovarian [66], breast [66,73], bladder [66], leiomyosarcoma 
[74], colon [75], pancreatic [76], and lung [77] cancers. Based on these promising 
preclinical results, a number of phase I and II clinical trials investigating the use 
of anti-CD47 monoclonal antibodies and recombinant SIRPa polypeptides in the 
treatment of both hematopoietic and solid tumors are currently underway [44]. 
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In addition to being a potential therapeutic target for human malignant 
melanoma, CD47 blockade has the potential to stimulate anti-tumor immune 
responses for the treatment of canine malignant melanoma. The CD47-SIRPa 
axis is conserved both biologically and functionally in canine tumor cells, and 
high affinity SIRPa variants have demonstrated efficacy in a mouse xenograft 
model of canine lymphoma [78]. 
3.5 CD47 blockade: mechanisms of action 
CD47 blockade mediates anti-tumor immunity through a variety of effector 
mechanisms (Figure 1-1). The majority of preclinical studies to date have 
investigated the effects of CD47 blockade on macrophage activation. These 
studies used fluorescent microscopy and flow cytometry to demonstrate an 
increase in macrophage-mediated phagocytosis of tumor cells in vitro following 
CD47 blockade [64-66,68]. The role of macrophages as the primary mediators of 
anti-tumor immunity following CD47 blockade has been supported by in vivo 
studies in which clodronate-mediated macrophage depletion abrogated the anti-
tumor effects of an anti-CD47 antibody [64,65]. CD47 blockade is also capable of 
promoting tumor regression in immunocompromised, B and T cell deficient mice, 
in which macrophages are the most likely effectors of an anti-tumor immune 
response [64-66]. In addition, CD47 blockade was shown to alter the activation 
state of tumor associated macrophages by converting these cells from an M2 
phenotype to a pro-inflammatory, anti-tumor (M1) phenotype [79]. There is also 
some evidence that CD47-blocking therapies promote additional recruitment of 
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macrophages. One study demonstrated that phagocytosis in response to CD47 
blockade stimulated the production of cytokines and chemokines, including 
monocyte-chemotactic protein 3 (MCP-3), that have the potential to recruit 
additional phagocytes to the tumor microenvironment [77]. Based on these 
studies, macrophages likely play a major role in the immune response following 
CD47 blockade. 
While enhanced macrophage-mediated phagocytosis is generally thought 
to be responsible for the anti-tumor effects of CD47 blockade, a number of other 
immune cells express SIRPa and are capable of responding to CD47-targeted 
therapies. One study demonstrated an increase in neutrophil antibody-dependent 
cellular cytotoxicity (ADCC) in a preclinical model of breast cancer following 
CD47 blockade [80]; however, this effect may be reliant on the specific anti-CD47 
antibody isotype used in the study [1]. Natural killer (NK) cells also express 
CD47, but the effects of CD47 blockade on NK cell activation are currently 
unclear: one study demonstrated NK cell-mediated ADCC of head and neck 
cancer cells following CD47 blockade [80] while another study found no direct 
effect of CD47 blockade on NK cell activity [65]. Further studies are needed to 
elucidate the effects of CD47-targeting therapies on NK cell activation. Finally, 
myeloid-derived dendritic cells (DCs) express SIRPa [81,82] and are capable of 
phagocytosing tumor cells in response to CD47 blockade [75,82,83]. In addition 
to regulating phagocytosis, ligation of SIRPa by CD47 suppresses DC maturation 
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and cytokine production [84], thus inhibiting DC activation and functional 
responses.  
In addition to activating the innate immune response, CD47 blockade 
promotes an anti-tumor adaptive immune response in immunocompetent mouse 
models. Treatment with anti-CD47 antibodies promotes antigen presentation by 
both macrophages and DCs in vitro [75,83]. In vivo, adoptive transfer of 
macrophages following CD47-mediated phagocytosis of colon cancer cells was 
able to protect immunocompetent mice from subsequent tumor challenge [75]. 
Another study using preclinical models of lung cancer and lymphoma 
demonstrated that the anti-tumor effects of CD47 blockade were reliant on cross-
presentation of antigens by CD11c+ DCs to CD8+ T cells. In this study, the 
therapeutic effects of CD47 blockade were abrogated in T cell-deficient mice, 
which indicates that T cells also play a key role in the anti-tumor response 
following CD47 blockade [83]. The effects of CD47-targeted therapies on the 
adaptive immune response suggest that these therapies may synergize with 
existing immunotherapies to promote anti-tumor immune responses. Although 
further exploration of immunotherapeutic combinations is needed, one study 
suggests CD47 blockade may synergize with anti-PD-1 therapy to mediate an 
anti-tumor immune response [85].  
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Figure 1-1: Mechanisms of action for CD47 targeting therapies. CD47 blockade 
has the ability to mediate anti-tumor immunity through several mechanisms. 
Macrophage-mediated phagocytosis can eliminate tumor cells directly and lead to the 
production of cytokines, such as MCP-3, which recruit additional macrophages to the 
tumor microenvironment. CD47 blockade may also convert pro-tumor, M2 
macrophages to a more anti-tumor, M1 phenotype. Depending on the isotype of the 
anti-CD47 antibody used, neutrophil ADCC may be induced through Fc dependent 
mechanisms. Finally, CD47 blockade can enable phagocytosis and antigen 
presentation to activate anti-tumor CD4+ and CD8+ T cells. (Figure based on ref [1]).  
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3.5 Combination strategies to enhance macrophage-mediated 
phagocytosis 
Therapeutic strategies that provide a pro-phagocytic stimulus have the 
potential to synergize with CD47 blockade to mediate tumor rejection. Indeed, 
there is some evidence that pro-phagocytic signals are required for phagocytosis 
following CD47 blockade. Although CD47 is expressed on both tumor cells and 
their normal cell counterparts, CD47 blockade leads to the selective elimination 
of tumor cells while the majority of normal cells fail to undergo phagocytosis 
[52,64,65]. To explain this contradictory result, one study examined cell surface 
expression of the pro-phagocytic signal calreticulin (CRT) and found that some 
tumor cells express CRT on their cell surface while normal cells do not (Figure 1-
2) [52]. shRNA knockdown of CRT abrogated the effects of CD47 blockade on 
phagocytosis, demonstrating that, in addition to blocking a “don’t eat me signal,” 
an “eat me” signal must be present for phagocytosis to occur [52]. Thus, 
treatment strategies which promote additional CRT expression, such as 
anthracycline chemotherapy, have the potential to synergize with CD47 
blockade. While promising, these combination strategies have yet to be 
examined in preclinical models. 
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Antibody Fc chains provide a robust stimulus for macrophage activation 
and phagocytosis [86], and a number of studies have examined the effects of 
combining anti-CD47 antibodies with tumor-specific antibodies capable of 
stimulating Fc-mediated functions. Combination CD47 blockade and rituximab or 
trastuzumab led to synergistic tumor elimination in preclinical models of NHL and 
breast cancer, respectively [65,80]. In addition, SIRPa monomers, which block 
CD47 but do not provide a Fc stimulus, synergized with rituximab, trastuzumab, 
Figure 1-2: Pro-phagocytic signals are necessary to enable phagocytosis 
following CD47 blockade. A. In the presence of CD47 blockade, normal, non-
apoptotic cells are not phagocytosed due to the lack of “eat me” signal 
expression. B. Some tumor cells express the “eat me” signal calreticulin (CRT) 
on their surface, but expression of CD47 inhibits the phagocytosis of these cells. 
C. In the presence of CD47 blockade, CRT provides a pro-phagocytic stimulus 
to macrophages, which results in tumor cell phagocytosis.  
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and cetuximab to promote tumor cell phagocytosis in vitro [68]. A number of 
these antibody combinations are currently under investigation in phase I clinical 
trials [44]. Again, these studies demonstrate that combining blockade of a “don’t 
eat me” signal with strategies to provide a “eat me” signal have the potential to 
synergistically result in an anti-tumor immune response.  
3.6 Modulation of phagocytic signals for the treatment of malignant 
melanoma 
 Although therapies targeting the CD47-SIRPa axis have demonstrated 
efficacy in a variety of hematopoietic and solid tumor types [64-66], the effect of 
blocking CD47 for the treatment of malignant melanoma is unclear. The first 
paper to evaluate the effects of CD47 blockade on melanoma growth treated a 
syngeneic mouse model of melanoma (B16 melanoma) using intravenous 
delivery of a CD47-targeting siRNA [87]. This paper showed a small increase in 
melanoma cell phagocytosis (from 2 to 14%) following siRNA knockdown of 
CD47 in vitro as well as a reduction in tumor volume following CD47 siRNA 
administration in vivo. Although effective, siRNA-mediated knockdown of CD47 is 
unlikely to be therapeutically relevant in clinical trials. A second paper examining 
the effects of CD47 blockade in a B16 mouse model of melanoma demonstrated 
no increase in tumor cell phagocytosis and no inhibition of tumor growth following 
treatment with a more therapeutically relevant anti-mouse CD47 nanobody [85]. 
This paper suggested CD47 blockade alone is insufficient to overcome immune 
resistance in melanoma. Finally, a recent article utilized an anti-CD47 antibody 
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for the treatment of primary human melanoma xenografts. This article 
demonstrated an increase in melanoma cell phagocytosis in vitro as well as a 
decrease in tumor metastasis in vivo following CD47 blockade [88]. The 
contradictory results of these studies indicate that a systematic evaluation of 
melanoma cell sensitivity to phagocytosis and to CD47 blockade is needed. In 
addition, the effects of modulating pro-phagocytic signals in combination with 
CD47 blockade has yet to be examined for the treatment of malignant 
melanoma. My objective in this dissertation was to characterize the anti-tumor 
immune response following modulation of pro-phagocytic and anti-phagocytic 
signals in malignant melanoma.  
In this study, we utilized a multi-species approach and compared the 
responses of human, mouse, and canine melanoma cells to phagocytosis. In 
order to provide a framework for preclinical testing, it is important to understand 
the similarities and differences in melanoma cell biology between species. 
Identifying similarities in tumors from multiple species could reveal evolutionarily 
conserved mechanisms of immunoevasion that are likely to be important for 
tumor cell survival. However, it is equally important to understand the differences 
in human melanoma cell biology as compared to mouse or canine cells in order 
to avoid over interpretation of data gained from animal models. Using a multi-
species approach to advance our understanding of how melanoma cells avoid 
elimination by the innate immune system may lead to the development of new 
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therapeutic strategies to improve patient responses and overcome resistance in 
the subset of patients who currently fail to respond to immunotherapies.   
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MATERIALS AND METHODS 
Cell lines and culture: Lymphoma cell lines: The CLBL-1 canine diffuse large B-
cell lymphoma cell line [89] was obtained from Dr. Barbara Rütgen (University of 
Vienna, Austria) and grown in Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Invitrogen, Carlsbad, California, USA) supplemented with 20% fetal bovine 
serum (Peak Serum, Fort Collins, Colorado, USA), 1% L-glutamine (Sigma-
Aldrich, St. Louis, Missouri, USA), and 100 µg/mL Primocin (Invitrogen, Carlsbad, 
California, USA). A20 mouse B cell lymphoma cells (ATCC, Manassas, Virginia, 
USA) and Raji human B cell lymphoma cells (ATCC, Manassas, Virginia, USA) 
were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (Peak 
Serum, Fort Collins, Colorado, USA), 1% L-glutamine (Sigma-Aldrich, St. Louis, 
Missouri, USA), 2 mM sodium pyruvate (Gibco, Gaithersburg, Maryland, USA), 
10 mM HEPES buffer (HyClone, Logan, Utah, USA), 1% non-essential amino 
acids (Gibco, Gaithersburg, Maryland, USA), and 100 µg/mL Primocin 
(Invitrogen, Carlsbad, California, USA). Melanoma cell lines: The M21 and M21-
GFP human melanoma cell lines were obtained from Dr. David Cheresh 
(University of California San Diego, USA). B16-OVA mouse melanoma cells were 
obtained from Dr. Ross Kedl (University of Colorado Denver, USA). Canine 
melanoma cell lines TLM1, CMGD2, and CMGD5 were obtained and cultured as 
described [90,91]. Breast cancer cell lines: The canine breast cancer cell line 
CMT12 was obtained from Dr. Curtis Bird (Auburn University, USA), and the 
feline breast cancer cell line K12 was obtained from Dr. Bill Hardy (Rockefeller 
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University, USA [92]). The mouse breast cancer cell line 4T1 was obtained from 
Dr. Kaylee Schwertfeger (University of Minnesota, USA) and was cultured in 
RPMI 1640 (Gibco, Gaithersburg, Maryland, USA) supplemented with 10% fetal 
bovine serum, 1% L-glutamine (Sigma-Aldrich, St. Louis, Missouri, USA), 2 mM 
sodium pyruvate (Gibco, Gaithersburg, Maryland, USA), 10 mM HEPES buffer 
(HyClone, Logan, Utah, USA), and 100 µg/mL Primocin (Invitrogen, Carlsbad, 
California, USA). Osteosarcoma cell lines: The canine osteosarcoma cell lines 
OSCA-40 and OSCA-78 were obtained and cultured as described [93]. The 
human osteosarcoma cell line SAOS2 was obtained from ATCC (Manassas, 
Virginia, USA), and the mouse osteosarcoma cell line K12 was obtained from the 
National Cancer Institute. Note: Both the feline breast cancer and mouse 
osteosarcoma cell lines were originally named K12. Throughout this manuscript, 
the feline cell line will be referred to as K12, and the mouse line as K12 mOS. All 
melanoma, osteosarcoma, and breast cancer lines as well as J774 macrophages 
(ATCC, Manassas, Virginia, USA) were cultured in Dulbecco’s Modified Eagle 
Medium (Thermo Fisher Scientific, Waltham, Massachusetts, USA) with 10% 
fetal bovine serum (Peak Serum, Fort Collins, Colorado, USA) and 100 µg/mL 
Primocin (Invitrogen, Carlsbad, California, USA) unless otherwise noted. 
Therapeutic agents: The high-affinity SIRPα protein CV1-hIgG4 [68] and the 
anti-CD47 monoclonal antibody Hu5F9-G4 [67] were produced as previously 
described and provided by Dr. Irving Weissman (Stanford University, USA). The 
corresponding isotype control antibody, huIgG4, the mouse anti-CD47 antibody 
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MIAP301, and its corresponding isotype control antibody, mIgG2a, were obtained 
from eBioscience (San Diego, California, USA). CD271 monoclonal antibody 
(clone ME20.4) was obtained from eBioscience (San Diego, California, USA).  
Detection of CD47 expression and blocking of the CD47/SIRPα axis: CD47 
expression was analyzed using Alexa Fluor 488 Hu5F9-G4, BV786 mouse anti-
human CD47 (Clone B6H12, BD Biosciences, San Jose, California, USA), or PE 
anti-mouse CD47 (Clone MIAP301, Biolegend, San Diego, California, USA). 
Briefly, 1x106 cells of each cell line were incubated with normal mouse 
immunoglobulin for 10 minutes on ice. Cells were subsequently labeled using 
Alexa Fluor 488 Hu5F9-G4, BV786 mouse anti-human CD47, PE anti-mouse 
CD47, or an isotype control antibody (Biolegend, San Diego, California, USA) 
and incubated on ice for 30 minutes. Analysis was performed using a LSRII flow 
cytometer (BD Biosciences, San Jose, California, USA), and geometric mean 
fluorescence intensity was determined using FlowJo (Tree Star, Ashland, 
Oregon, USA). To analyze the blocking ability of CV1-hIgG4, 1x106 cells of each 
line were incubated with varying concentrations of CV1-hIgG4 for 15 minutes on 
ice. Cells were subsequently labeled using Alexa Fluor 488 Hu5F9-G4 and 
incubated on ice for 30 minutes. Analysis was performed as described above, 
and data were fit to sigmoidal dose-response curves using Prism 6 (GraphPad, 
La Jolla, California, USA). 
Macrophage phagocytosis assays: J774 mouse macrophages were activated 
24 hours prior to phagocytosis assays using 100 ng/mL recombinant mouse IFNγ 
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(eBioscience, San Diego, California, USA). Cancer cells used in the assay were 
either GFP+ or labeled with CFSE according to the manufacturer’s protocol 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA). Cancer cells were 
incubated with CD47 blocking reagents or isotype controls (10 µg/mL) for 30 
minutes prior to the assay. 50,000 J774 mouse macrophages were then co-
cultured in 96 well non-adherent plates with 50,000 cancer cells (1:1 ratio). 
Phagocytosis in response to therapeutic treatments was evaluated after two 
hours of co-culture and analyzed by flow cytometry (Figure 2-1). Macrophages 
were identified by staining with PE/Cy7 or APC-anti-mouse F4/80 as described 
above (Biolegend, San Diego, California, USA). Phagocytosis was evaluated 
using a LSRII flow cytometer (BD Biosciences, San Jose, California, USA) and 
analyzed using FlowJo (Tree Star, Ashland, Oregon, USA) as the percentage of 
F4/80+ J774 cells that engulfed CFSE+/GFP+ tumor cells per total F4/80+ 
population (Figures 2-2, 2-3). Dead cells were excluded using propidium iodide 
(PI, Biolegend, San Diego, California, USA) to eliminate non-specific staining. If 
excessive macrophage or tumor cell death occurred (macrophages represented 
<40% or >60% of the total cell population), the assay was not included in the final 
analysis as the assay is designed to test a 1:1 macrophage: tumor cell ratio. This 
occurred in approximately 2% of phagocytosis assays performed. For soluble 
factor assays, Raji cells and J774 macrophages were suspended in supernatant 
harvested from cultured M21 melanoma cells titrated with new IMDM medium for 
the duration of the phagocytosis assay. Alternatively, M21 cells and J774 
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macrophages were suspended in supernatant harvested from cultured Raji 
melanoma cells titrated with new IMDM medium for the duration of the 
phagocytosis assay.  
 
  
Figure 2-1: Schematic of phagocytosis assays 
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Figure 2-2: Schematic of the gating scheme for phagocytosis assays. Analysis 
was performed in FlowJo v10.2. Gates are set based on unstained cells or 
macrophages stained with PE-Cy7 F4/80 alone.  
  
38 
 
Chemotherapeutic Treatment: B16-OVA cells were treated with 0.03 µM 
doxorubicin chemotherapy (Teva Parenteral Medicines, Inc, Israel) for 24 hours 
prior to analysis or to placement in a phagocytosis assay (as described above). 
To analyze pro-phagocytic signal expression, cells were harvested and stained 
with propidium iodide and APC Annexin V according to the manufacturer’s 
protocol (Biolegend, San Diego, California, USA). Display of membrane 
phosphatidylserine exposure was evaluated by flow cytometry and is represented 
Figure 2-3: Rationale for the phagocytosis assay gating scheme. Populations 3 
and 4 have the potential to contain whole cell phagocytosis; therefore, the phagocytosis 
gating scheme includes these two populations.   
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by the %Annexin V+PI- cells. Alternatively, cells were labeled with an Alexa Fluor 
647 anti-mouse calreticulin antibody (clone ERP3924, Abcam, Cambridge, 
United Kingdon) and incubated on ice for 30 minutes prior to flow cytometry 
analysis on a LSRII flow cytometer (BD Bioscience, San Jose, California, USA) 
and data analysis using FlowJo (Tree Star, Ashland, Oregon, USA).   
Brefeldin A Treatment: M21-GFP or Raji cells labeled with CFSE were 
incubated with 5.0 µg/mL Brefeldin A solution (Biolegend, San Diego, California, 
USA) for two hours prior to placement in a phagocytosis assay (as described 
above). 5.0 µg/mL Brefeldin A solution was added to the phagocytosis assay 
medium to ensure continued secretory inhibition.  
Clustering of TCGA expression data for extracellularly expressed proteins: 
The results published here are in whole or part based upon data generated by 
the TCGA Research Network: http://cancergenome.nih.gov/. Uniformly 
processed TCGA expression data in transcripts per million (TPM) was obtained 
from GEO accession GSE62944 [94]. Extracellular genes were identified using 
the COMPARTMENTS database [95] and GOType labels plasma membrane, 
cell surface, extracellular region, extracellular matrix and a score > 4. Expression 
data for these extracellular genes (n = 5,082) in the cancer types of interest 
(DLBC, COAD, BRCA, LUAD, LUSC and SKCM) was isolated and used in 
further analysis.  Variance of expression was calculated for each gene across all 
tumor samples and the top 500 most variable genes were clustered based on 
gene expression values using Euclidean distance.   
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siRNA literature-based selection: 48 genes were included in the siRNA panel 
(Table 2-1). All of these genes (except Bcl-2) are expressed on the surface of 
melanoma cells based on a literature search (PubMed) and using the 
COMPARTMENTS online subcellular localization database [95]. Bcl-2 was 
chosen as a control on the basis that siRNA knockdown of this gene should 
increase cell apoptosis. The other genes were chosen based on 1 of 4 criteria: 
(1) the gene has been identified as a “don’t eat me” signal in the literature, (2) 
gene expression is restricted almost exclusively to melanoma cells, (3) the gene 
has been shown to contribute to melanoma cell growth and metastasis or (4) the 
gene has been associated with immune suppression in the tumor 
microenvironment. Some of the genes selected are also expressed on 
phagocytosis-sensitive cells; however, we did not exclude these genes as 
melanoma cells may post-translationally modify these proteins in a way that 
causes them to act as an anti-phagocytic signal. 
Gene 
Symbol 
Gene Name Rationale References 
BCL2 Bcl-2 Anti-apoptotic protein; siRNA KD should 
increase cell death (control) 
[96] 
CD200 CD200 “Don’t eat me” signal expressed on myeloid 
cells and the CNS; binds to CD200R on 
macrophages to inhibit macrophage 
activation (role in phagocytosis unclear) 
[48] 
PECAM1 Pecam-1 or CD31 “CD31 prevents phagocyte engulfment of 
leukocytes in a homophilic manner by 
transmitting detachment signals from the 
phagocyte...Thus, CD31 functions as a 
don’t eat me signal by regulating tethering 
between the phagocyte and the target cell.” 
Also interacts with avb3 integrin (see the av 
or b3 integrin sections) 
[48,97] 
Table 2-1: Rationale for siRNA gene selection 
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CD151 CD151 Tetraspanin. Promotes B16F10 metastasis 
and melanoma cell invasion. Expressed on 
the plasma membrane of human melanoma 
cells 
[98,99] 
CD81 CD81 Tetraspanin. Enhances melanoma cell 
motility and invasion. Expressed on the 
surface of melanoma cells. Shown to have 
an immunosuppressive role in the TME 
(promotes Treg and MDSC function)  
[100,101] 
SERPINE1 PAI-1 Expressed on neutrophils and endothelial 
cells. Acts as a “don’t eat me” signal; 
however, the receptor on macrophages is 
unknown (may inhibit CRT) 
[48] 
ANXA1  Annexin 1 Anti-inflammatory mediator. Inhibits 
macrophage PG and NO production. 
Inhibits phagocytic activity of peritoneal 
macrophages 
[102] 
MIF Macrophage 
migration 
inhibitory factor 
(MIF) 
Necessary for MDSC activation and 
immune suppression. Inhibits macrophage 
migration. Promotes melanoma cell 
proliferation, cell survival, and anchorage-
independent growth. Poor prognostic 
indicator in melanoma 
[103,104] 
SELPLG PSLG-1 Augments the growth and metastasis of 
B16 melanoma. However, absent on other 
tested melanoma cell lines. Has been 
shown to act as a T cell checkpoint 
molecule 
[105,106] 
ECM1 Extracellular 
matrix protein 1 
Overexpressed in melanoma; important for 
melanoma cell attachment 
[107] 
CDH1 Cadherin-1 (E-
cadherin) 
Expressed in melanoma cells; associated 
with benign/low grade tumors. Loss of 
CDH1 correlates with metastasis. Increases 
growth through beta-catenin signaling; 
plays a role in the early metastatic cascade  
[97,108,109] 
CDH2 Cadherin-2 (N-
cadherin) 
Expressed in melanoma cells; associated 
with high grade/metastatic tumors. Loss of 
CDH1 and gain of CDH2 correlated with 
metastasis. Increases melanoma cell 
survival, metastasis, and invasion. Mediates 
communication between melanoma cells 
and fibroblasts 
[97,109] 
CDH3 Cadherin-3 (P-
cadherin) 
Expressed in melanoma cells; associated 
with benign/low grade tumors 
[110,111] 
CLDN1 Claudin 1 Overexpressed in melanoma; contributes to 
melanoma cell motility, invasion, and MMP 
expression 
[112] 
CLDN12 Claudin 12 Expressed in melanoma cells [113] 
ALCAM Activated 
leukocyte cell 
adhesion 
molecule or 
CD166 
Mediates cell-cell adhesion in invading 
melanoma. 
Regulates adherens junctions and may 
increase invasiveness 
[114,115] 
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MCAM  Melanoma cell 
adhesion 
molecule or 
CD146 or MUC18 
Mediates cell-cell adhesion in melanoma; 
overexpression activates the AKT pathway 
in melanoma. Increases MMP-2 expression 
to promote invasion. Upregulates FAK to 
protect cells from anoikis. Contributes to 
melanoma metastasis and tumorigenicity. 
Binds to galectin-1 on immune cells and 
endothelial cells to dampen anti-tumor 
immunity and promote angiogenesis 
[114,116,117] 
NCAM1 Neural cell 
adhesion 
molecule 1 
Potentiates melanoma cell growth, invasion, 
and metastasis. Regulates Wnt signaling in 
B16 cells 
[118] 
CEACAM1 Carcinoembryonic 
antigen-related 
cell adhesion 
molecules 1 
Expressed in melanoma; correlates with 
metastatic spread, invasion, tumor growth. 
Linked to inflammation and angiogenesis 
[119] 
BCAM Basal cell 
adhesion 
molecule 
BCAM has an amino acid sequence with 
structural homology to MUC18; may have 
related effects on phagocytosis (could see 
multiple hits by targeting similar genes) 
[120] 
L1CAM L1 cell adhesion 
molecule 
Overexpressed in melanoma; associated 
with poor prognosis and advanced disease. 
Induces a motile and invasive phenotype 
and supports aggressive tumor growth, 
metastasis, and chemoresistance. Can 
interact with several integrins to promote 
cell adhesion and motility. Can activate 
NFkB in tumor cells to promote growth 
[121] 
MADCAM1 Mucosal vascular 
addressin cell 
adhesion 
molecule-1 
Expressed on B16 cells; may play a role in 
melanoma cell aggregation/homotypic 
interactions 
[122] 
EPCAM Epithelial cell 
adhesion 
molecule 
Not expressed in most melanomas; is 
involved in macrophage-tumor cell fusions 
isolated from the blood of melanoma 
patients.  
[123] 
F11R Junctional 
adhesion 
molecule A (JAM-
A) 
Involved in melanoma cell transmigration [124] 
JAM3 Junctional 
adhesion 
molecule C (JAM-
C) or 3 
Involved in melanoma cell transmigration 
and metastasis 
[124,125] 
ITGAV Integrin alpha v 
subunit 
In most melanomas, the αv subunit forms 
complexes with the β1, β3, β5, or β6 
subunits.  Expressed regardless of disease 
stage. avb3 integrin expression correlates 
with poor prognosis and metastasis. In vitro 
blockade assays suggest a role in growth 
and invasion. However, effects may depend 
on stage; it has been suggested that avb3 
plays a critical role in the transition from 
[97] 
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radial to vertical growth phases. Plays a 
role in localizing MMP-2 to the cell surface 
and in transendothelial migration through 
PECAM/L1 interactions.  
ITGA2 Integrin alpha 2 
subunit 
Expression on advanced 
tumors/metastasis. Involved in melanoma 
progression and motility, correlates with 
metastasis.  
[126] 
ITGA3 Integrin alpha 3 
subunit 
Overexpressed in 85% of human metastatic 
melanoma; expressed in all canine lines 
tested. Associated with increased cell 
motility, invasiveness, and metastasis in 
mouse models 
[127] 
ITGA4 Integrin alpha 4 
subunit  
Expressed on melanoma cells; may 
mediate adhesion to activated endothelial 
cells during metastasis 
[128] 
ITGA5 Integrin alpha 5 
subunit  
Expressed on melanoma; may be involved 
in invasion of the basement membrane and 
metastasis 
[128] 
ITGA6 Integrin alpha 6 
subunit 
Expressed on melanoma in low levels; pairs 
with β1 as a laminin receptor 
[128] 
ITGA7 Integrin alpha 7 
subunit 
Expressed on melanoma cells (complexed 
with β1). Rarely expressed on other cancer 
types 
[128] 
ITGB1 Integrin beta 1 
subunit 
Pairs with av to mediate melanoma cell 
attachment to the basement membrane 
[128] 
ITGB3 Integrin beta 3 
subunit 
In most melanomas, the β3 subunit 
predominantly pairs with the αv subunit. 
Primarily expressed in the vertical growth 
phase; correlates with poor prognosis. avb3 
integrin expression correlates with poor 
prognosis and metastasis. In vitro blockade 
assays suggest a role in growth and 
invasion. However, the effects may depend 
on stage; it has been suggested that avb3 
plays a critical role in the transition from 
radial to vertical growth phases. Plays a 
role in localizing MMP-2 to the cell surface 
and in transendothelial migration through 
PECAM/L1 interactions. 
[97] 
ITGB4 Integrin beta 4 
subunit 
Expressed by B16 cells. Involved in 
metastasis: binds to ligands on endothelial 
cells during transmigration to the lung. 
Associated with FAK complexing, 
activation, and signaling. 
[129] 
ITGB5 Integrin beta 5 
subunit 
Expressed in M21 melanoma cells; involved 
in adhesion to vitronectin  
[130] 
ICAM1 Intercellular 
adhesion 
molecule 1 
Expressed on melanoma cells [131] 
AGER Advanced 
glycosylation end-
Upregulated in melanoma; levels are 
highest in stage 4 melanoma. Involved in 
melanoma cell metastasis 
[132,133] 
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product specific 
receptor or RAGE 
LGALS1 Galectin-1 Expressed by immune cells, endothelial 
cells, and some cancer cells. Proangiogenic 
effects, protects melanoma cells from the 
action of anti-tumor cytolytic T-cells, confers 
chemoresistance.  
[134] 
LGALS3 Galectin-3 Involved in melanoma metastasis and 
invasion; increases MMP activity. Leads to 
T cell apoptosis in the tumor 
microenvironment. Stimulates 
angiogenesis.  
[134] 
DSC3 Desmocollin 3 
 
Expression is associated with a lack of a 
Th1 immune signature in melanoma 
[135] 
CAV1 Caveolin 1 Expressed in melanoma; mediates beta-
catenin signaling to promote 
melanomagenesis and metastasis 
[136] 
ST8SIA1 Ganglioside GD3 
synthase 
 
Type II membrane protein that catalyzes the 
transfer of sialic acid from CMP-sialic acid 
to GM3 to produce gangliosides GD3 and 
GT3. GD3 enhances melanoma cell 
adhesion and recruits integrins to lipid rafts 
[137,138] 
MLANA Melan-A, MART-
1, melanoma 
antigen 
recognized by T-
Cells 1 
Melanoma antigen often used for IHC 
diagnosis of melanoma. Expression very 
restricted to melanoma; often used as an 
antigen to activate anti-tumor CD8+ cells 
[139,140] 
PMEL Melanocytes 
lineage-specific 
antigen GP100 
premelanosome 
protein 
Melanocyte-specific type I transmembrane 
glycoprotein. Expression very restricted to 
melanoma; often used as an antigen to 
activate anti-tumor CD8+ cells 
[141] 
TRPC1 TRP-1 
 
Commonly used melanoma antigen in anti-
tumor immune studies; melanosomal 
protein used as a differentiation marker. 
Expression restricted to melanoma.  
[142] 
MFGE8 Milk fat globule-
EGF factor 8 
protein 
Expressed at high levels during the vertical 
growth phase of melanoma. Coordinates 
avb3 integrin signaling; enhances 
tumorigenicity and metastasis through Akt 
and Twist pathways. Bridging molecule: 
binds exposed PS on apoptotic cells and 
avb5 integrin on macrophages to promote 
efferocytosis. Efferocytosis leads to an anti-
inflammatory response (decreased antigen 
cross-presentation by DCs, increased Treg 
production, M2 polarization, and decreased 
TIL activation).  
[143,144] 
PXN Paxillin Role in melanoma growth, adhesion, and 
metastasis 
[138] 
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siRNA Mediated Knockdown: ON-TARGETplus siRNA pools targeting 48 
melanoma proteins, siRNAs targeting CD47, the non-targeting control siRNA 
pool, and the siGLO Red Transfection Indicator were validated by and purchased 
from Dharmacon (Lafayette, Colorado, USA). Utilizing a random number 
generator, we combined the 48 siRNAs into pools of three siRNAs plus a siRNA 
targeting CD47 (Figure 2-4). Each siRNA was used in four different pools. siRNA 
pools were tested in seven groups, each with its own set of controls 
(untransfected M21 cells, M21 cells transfected with non-targeting siRNA, and 
Raji lymphoma cells as a positive control for phagocytosis). 230,000 M21-GFP 
cells were plated 24 hours prior to transfection in antibiotic-free DMEM medium. 
Cells were transfected using TransIT-TKO reagent (Mirus Bio LLC, Madison, 
Wisconsin, USA) according to the manufacturer’s protocol with either 100 µM of 
each siRNA in the pool or 400 µM non-targeting control siRNA. Cells were 
cultured for 48 hours prior to analysis or placement in a phagocytosis assay (as 
previously described).  
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RNA preparation and quantitative reverse-transcriptase PCR (qRT-PCR): 
RNA was isolated and purified from cells using a RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and concentrations were measured using a NanoDrop ND-
1000 UV–vis spectrophotometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). cDNA was synthesized using a QuantiTect Reverse 
Transcription Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
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Figure 2-4: Schematic of siRNA knockdown assays 
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protocol. Eight genes targeted in the siRNA pool were chosen by a random 
number generator and checked to ensure that multiple protein families were 
represented by these genes. Primers were designed using NCBI’s Primer Blast 
tool (see Table 2.2 for primer sequences). qRT-PCR was performed using a 
LightCycler® 96 (Roche Applied Science, Basel, Switzerland) with FastStart 
SYBR Green Master Mix (Roche Applied Science, Basel, Switzerland). Samples 
in which the template was omitted were used as negative controls. Relative 
mRNA values were expressed as delta-Ct values normalized to GAPDH.  
Table 2-2: Primer Sequences for qRT-PCR 
Gene ID Forward Primer (5’-3’) Reverse Primer (5’-3’) 
CD47 CAACCTCCTAGGAATAACTGAAGT
G 
GGGTCTCATAGGTGACAACCAG 
CD81 AATTTCGTCTTCTGGCTGGCT CCAACGAACATCATGACAGCG 
MCAM TGGGCGCTGTCCTCTATTTC GTTCGCTCTTACGAGACGGG 
JAM3 GACAAGTGACCCCAGGATCG ACCTCACAGCGATAAAGGGC 
ICAM1 TGACCGTGAATGTGCTCTCC TCCCTTTTTGGGCCTGTTGT 
LGALS1 CCTGACGCTAAGAGCTTCGT GGAAGGGAAAGACAGCCTCC 
MLANA TGTGCCCTGACCCTACAAGA AATACCAACAGCCGATGAGCA 
 
Harvest of bone-marrow derived macrophages: C57BL/6J mice were 
euthanized according to IACUC guidelines (IACUC Protocol 1406-31578A). Bone 
marrow was harvested by flushing the excised femur and tibia with sterile PBS. 
Macrophages were cultured in IMDM medium with 10 ng/mL GM-CSF and 
enriched by adherence in cell culture for one week prior to use.  
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Harvest of OT-I and OT-II T cells: OT-I.PL mice (generated by crossing OVA257–
264/H-2K
b specific, TCR transgenic OT-I mice with Thy1-congenic B6.PL-
Thy1a/Cy (Thy1.1) mice and breeding to homozygosity) were generously 
provided by Dr. Matthew Mescher (University of Minnesota). OT-II.PL mice 
(generated by crossing OVA323–339/I-A
b specific, TCR transgenic OT-II mice with 
Thy1-congenic B6.PL-Thy1a/Cy (Thy1.1) mice and breeding to homozygosity) 
were generously provided by Dr. Marc Jenkins (University of Minnesota). 
Experiments were conducted under specific pathogen-free conditions and 
performed in compliance with relevant laws and guidelines, and with approval of 
the Institutional Animal Care and Use Committee at the University of Minnesota 
(breeding and harvest of OT-I/II mice: IACUC Protocol 1210A22387; tumor 
experiments: IACUC Protocol 140631578A). OT-I and OT-II T cells were 
harvested as previously described [145]. Briefly, “inguinal, axillary, brachial, 
cervical, and mesenteric lymph nodes (LN) were harvested from OT-I/PL mice, 
pooled, and disrupted to obtain a single cell suspension. OT-I/PL LN cells were 
enriched for CD8+CD44low cells by negative selection using MACS magnetic cells 
sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were coated with 
FITC-labeled antibodies specific for CD4, B220, I-Ab, CD11c, and CD44. Anti- 
FITC magnetic MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were 
added to the cells, which were passed over separation columns attached to the 
MACS magnet. The cells that did not bind to the column were collected and were 
95% CD8+ and 0.5% CD44high” [145]. OT-II T cells were purified in a similar 
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fashion, selecting for CD4+CD44low cells to 80% purity. For assays in which T 
cells were activated in vitro, OT-I and OT-II cells were stimulated in flat-bottom 
microtiter wells coated with DimerX H-2Kb-Ig fusion protein (BD Biosciences, San 
Jose, California, USA) loaded with OVA257-264 peptide (New England Peptide, 
Gardner, Massachusetts, USA) and recombinant B7-1/Fc chimeric protein (R&D 
Systems, Minneapolis, Minnesota, USA). OT-I cells were cultured in RPMI 1640 
(Gibco, Gaithersburg, Maryland, USA) supplemented with 2% L-glutamine 
(Gibco, Gaithersburg, Maryland, USA), 1% penicillin-streptomycin 
(LifeTechnologies, Carlsbad, California, USA), 1% HEPES (Gibco, Gaithersburg, 
Maryland, USA), 1% NEAA (Sigma-Aldrich, St. Louis, Missouri, USA), 1% 
sodium pyruvate (Gibco, Gaithersburg, Maryland, USA), 0.05% 2-ME (Gibco, 
Gaithersburg, Maryland, USA), and 10% fetal bovine serum (Atlas Biologicals, 
Fort Collins, Colorado, USA). 0.5x106 OT-I cells were added to each well along 
with 2.5ng/mL recombinant mouse IL-12 (R&D Systems, Minneapolis, 
Minnesota, USA) and cultured for 3 days prior to analysis.  
In vitro T cell activation assays: B16-OVA cells were treated with 0.03 µM 
doxorubicin chemotherapy or an equivalent amount of PBS for 24 hours (Figure 
2-5). Cells were placed in a phagocytosis assay with primary bone-marrow 
derived macrophages in the presence or absence of CD47 blockade (as 
described above). Following the phagocytosis assay, macrophages were isolated 
using magnetic cell sorting with CD11b magnetic beads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) according to the manufacturer’s protocol. To 
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assess macrophage purity, populations obtained by cell sorting were labeled with 
an anti-mouse F4/80 antibody (PE-Cy7, Biolegend, San Diego, California, USA) 
and incubated on ice for 30 minutes prior to flow cytometry analysis on a LSRII 
flow cytometer (BD Bioscience, San Jose, California, USA) and data analysis 
using FlowJo (Tree Star, Ashland, Oregon, USA). Macrophage purity was 
consistent between the treatment groups (60-80%). Purified macrophages were 
incubated with OT-I and OT-II T cells at a 0.1:1, 0.25:1, 0.5:1, or 1:1 
macrophage: T cell ratio to allow antigen presentation to occur. Supernatant was 
harvested from the cultures at 24, 48, 72, and 96 hours of incubation and 
analyzed for IFNg and IL-2 production by ELISA according to the manufacturer’s 
protocols (Biolegend LegendMax ELISA kits, San Diego, California, USA). Cells 
were harvested at the assay endpoint and labeled with an anti-mouse CD11b 
antibody (PE-Cy7), anti-mouse CD69 antibody (PE), anti-mouse CD44 antibody 
(FITC), anti-mouse CD8 antibody (Pacific Blue), and anti-mouse CD4 antibody 
(APC) (eBioscience, San Diego, California, USA). Cells were incubated on ice for 
30 minutes prior to flow cytometry analysis on a LSRII flow cytometer (BD 
Bioscience, San Jose, California, USA) and data analysis using FlowJo (Tree 
Star, Ashland, Oregon, USA). 
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In vivo T cell activation assay: Experiments were conducted under specific 
pathogen-free conditions and performed in compliance with relevant laws and 
guidelines, and with approval of the Institutional Animal Care and Use Committee 
at the University of Minnesota (IACUC Protocol 1406-31578A). Syngeneic 
CD45.2 C57BL/6 recipient mice were injected subcutaneously (SC) with 2x105 
B16-
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Phagocytosis 
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Figure 2-5: Schematic of experimental design to assess the effects of 
doxorubicin chemotherapy and CD47 blockade on in vitro T cell activation  
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B16-OVA cells (Figure 2-6). Once tumors were visibly established (9 days after 
implantation), mice received intraperitoneal (IP) injections of the anti-mouse 
CD47 antibody, MIAP301, or control mouse IgG2a (200 μg i.p.) on days 9 and 
11. On day 13, OT-I and OT-II T cells were harvested and purified as described 
above and labeled with CellTrace Violet (CTV) according to the manufacturer’s 
instructions (Thermo Fisher, Waltham, Massachusetts, USA). Prior to transfer, 
the cells were analyzed by flow cytometry (LSRII BD Biosciences, San Jose, 
California, USA) to assess CD8+ and CD4+ cell purity. The activation markers 
CD25, CD69, and CD44 were also assessed to ensure the cells were not 
activated prior to adoptive transfer. Transferred OT-I cells were >90% CD8+ and 
OT-II cells were >75% CD4+. 1x106 of each OT-I and OT-II cells were transferred 
via the tail vein into recipient mice. As negative controls, one non-tumor bearing 
mouse received OT-I and OT-II cells, and one tumor-bearing mouse did not 
receive OT-I or OT-II cells. As a positive control, one tumor-bearing mouse 
received OT-I and OT-II cells along with 50 μg OVA257–264  peptide and 50 μg 
OVA323–339 peptide resuspended in PBS. Three days following adoptive transfer, 
the tumor draining lymph node, non-draining (contralateral) lymph node, and 
tumor were harvested from each mouse and homogenized into a single cell 
suspension. Cells were labeled with antibodies against CD8, CD4, CD69, CD44, 
Thy1.1, and CD45.1. Adoptively transferred cells were identified by congenic 
markers and CTV labeling. T cell activation and percent division was assessed 
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by CTV dilution. Analysis was performed in FlowJo (Tree Star, Ashland, Oregon, 
USA).  
 
In vivo T cell activation assay with doxorubicin: T cell activation assay was 
performed as described above. In this experiment, mice received 5 mg/kg 
doxorubicin chemotherapy on day 10, and OT-I and OT-II T cells were 
transferred 4-6 hours after the second antibody injection (Figure 2-7). Controls 
were utilized as described above. Analysis was performed as described above.  
Figure 2-6: Schematic of the experimental design to assess the effects of CD47 
blockade on antigen-specific T cell activation in vivo 
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Figure 2-7: Schematic of the experimental design to assess the effects of CD47 
blockade and doxorubicin chemotherapy on antigen-specific T cell activation in vivo 
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Chapter 3 
 
Melanoma displays a unique resistance to 
phagocytosis that cannot be mitigated by  
CD47 blockade 
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Rationale and Objectives: Therapies which inhibit the CD47/SIRPa axis have 
been shown to increase tumor cell phagocytosis in vitro and anti-tumor immune 
responses in vivo in a number of preclinical models, including both hematopoietic 
and solid tumors [64-66,83], but the effect of modulating pro- and anti-phagocytic 
signals for the treatment of malignant melanoma remains unknown. In this 
chapter, our objective was to characterize the anti-tumor immune response to 
melanoma following CD47 blockade.  
 
Results 
Mouse melanoma cells display resistance to phagocytosis that is not fully 
mitigated by CD47 blockade 
 To determine whether the anti-phagocytic signal CD47 protects melanoma 
cells from macrophage-mediated phagocytosis, we utilized the mouse B16F10 
cell line, which is a well-characterized, preclinical model of melanoma [146]. In 
addition, we utilized mouse A20 lymphoma cells, which have demonstrated 
sensitivity to CD47 blockade [65,83], as a positive control. We first evaluated 
CD47 protein expression on B16 melanoma and A20 lymphoma cells by flow 
cytometry. We confirmed surface expression of CD47 in both cell types (Figure 
3-1A). The expression of CD47 on B16 cells suggests that this innate immune 
checkpoint could be a therapeutic target in melanoma.  
To block the CD47/SIRPa axis in this model system, we utilized two 
different reagents: a high-affinity SIRPa-Fc fusion protein, CV1-hIgG4 [68], and 
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an anti-mouse CD47 monoclonal antibody, MIAP301 [83]. To assess the ability of 
CV1-hIgG4 to block CD47 on the surface of mouse cells, we incubated B16 and 
A20 cells with increasing concentrations of unlabeled CV1-hIgG4, followed by 
staining with a fluorescently-conjugated anti-CD47 antibody (PE MIAP301). CV1-
hIgG4 competitively blocked interactions between the anti-CD47 antibody and 
mouse CD47 expressed on the surface of both cell types (Figure 3-1B and 3-1C).  
The ability of MIAP301 to block CD47 on A20 cells has been previously 
established in the literature [83], but this reagent’s use in B16 cells has not been 
reported. Therefore, we performed similar blocking assays using increasing 
concentrations of unlabeled MIAP301 followed by staining with a fluorescently-
conjugated mouse recombinant SIRPa to assess the effect of MIAP301 on B16 
cells. Higher concentrations of MIAP301 were needed to block the interactions 
between rSIRPa and mouse CD47 compared to CV1-G4 (Figure 3-1D); however, 
the concentration needed to effectively block CD47 was well below the 
concentration we used in subsequent phagocytosis assays. Therefore, both CV1-
G4 and MIAP301 are efficacious CD47 blocking reagents in the mouse model.   
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To evaluate the ability of CD47 blockade to enhance phagocytosis of 
mouse melanoma cells in vitro, we incubated CFSE-labeled B16 cells with 
activated mouse J774 macrophages in the presence or absence of CV1-hIgG4. 
Phagocytosis was evaluated by flow cytometry and measured as the percent of 
F4/80+ J774 macrophages that engulfed CFSE+ tumor cells per total F4/80+ 
population. Phagocytosis of A20 lymphoma cells was evaluated as a positive 
Figure 3-1: CD47 expression and blockade on mouse tumor cell lines. A. CD47 
expression on target cells. Labeling of mouse melanoma (B16-OVA) and lymphoma (A20) 
cell lines with the anti-CD47 mAb MIAP301 conjugated to PE was detected by flow 
cytometry. B and C. Efficacy of CD47 blockade with CV1-G4 on (B) B16 melanoma cells 
and (C) A20 lymphoma cells. Cells were incubated with unlabeled CV1-G4 at the 
indicated concentrations for 15 minutes, followed by subsequent labeling with PE-
MIAP301 to detect unoccupied CD47 binding sites. D. Efficacy of CD47 blockade with 
MIAP301 on B16 melanoma cells. Cells were incubated with unlabeled MIAP301 at the 
indicated concentrations for 15 minutes, followed by subsequent labeling with PE-rSIRPa 
to detect unoccupied CD47 binding sites. 
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control. A20 lymphoma cells displayed a high level of phagocytosis in the 
absence of antibodies (average of 43.1 ± 5.2%), which was further increased 
upon the addition of CV1-G4 (to 60.3 ± 7.5%, Figures 3-2A and 3-2B) and upon 
the addition of MIAP301 (to 51.0% ± 6.8%, Figures 3-2C and 3-2D).  In contrast, 
B16 cells were poorly phagocytosed by J774 macrophages in the absence of 
antibodies (average of 6.4 ± 1.2%, Figures 3-2A-D). Treatment with CV1-hIgG4 
or MIAP301 lead to a modest increase in melanoma cell phagocytosis (to 10.6 ± 
3.9% and 12.8 ± 3.2%, respectively). However, the overall level of melanoma cell 
phagocytosis remained low compared to sensitive lymphoma cells (Figures 3-2A-
D). We observed similar results using primary mouse bone-derived 
macrophages, demonstrating that the defect in phagocytosis is not macrophage 
dependent (data not shown). These findings show that mouse melanoma cells 
display a resistance to phagocytosis that cannot be fully mitigated by CD47 
blockade alone.  
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Figure 3-2: Mouse melanoma cells display resistance to phagocytosis that is 
not fully mitigated by CD47 blockade. Phagocytosis of mouse tumor cells. CFSE-
labeled tumor cells were incubated with J774 macrophages in the presence of (A) 
control IgG4 or CV1-G4 (C) IgG2a or MIAP301. Phagocytosis was quantified as the 
percent of F4/80+ J774 cells that engulfed CFSE+ tumor cells per total F4/80+ 
population. Flow cytometry plots representing the mean percent phagocytosis are 
shown. B. Quantification of phagocytosis assays from Figure A. For B16-OVA cells, 
bars represent 6 experiments repeated in triplicate (mean± SEM); p=0.7850, Kruskal-
Wallis test. For A20 cells, bars represent 3 experiments (mean± SEM); p=0.3259, 
Kruskal-Wallis test. D. Quantification of phagocytosis assays from Figure C. For B16-
OVA cells, bars represent 5 experiments (mean± SEM); p=0.5375, Kruskal-Wallis 
test. For A20 cells, bars represent 4 experiments repeated in triplicate (mean± SEM); 
p=0.2480, Kruskal-Wallis test. 
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CD47 blockade fails to initiate an anti-tumor adaptive immune response or 
mediate B16 melanoma tumor rejection  
 In preclinical models, including a syngeneic model using A20 lymphoma 
cells, phagocytosis in response to CD47 blockade has been shown to elicit an 
anti-tumor adaptive immune response through antigen cross-presentation and 
priming of cytotoxic CD8+ T cells [75,83]. Therefore, despite observing only a 
small increase in B16 melanoma cell phagocytosis in response to CD47 
blockade (Figure 3-2), we sought to characterize whether this increase could 
similarly improve anti-tumor T cell responses in vivo.   
 To assess T cell activation, we utilized the transplantable B16F10 mouse 
melanoma cell line (haplotype H2b) stably transfected with chicken ovalbumin 
(B16-OVA). This system allows the quantification of antigen-specific T cell 
responses using T cells with transgenic receptors that recognize OVA peptides 
presented in the context of class I (OT-I) and class II (OT-II) MHC [147,148]. 
B16-OVA is a syngeneic tumor capable of growing in an immunocompetent 
C57BL/6 mouse, which allows us to study in vivo anti-tumor immune responses.  
 Prior to assessing the anti-tumor T cell response following CD47 
blockade, we performed a series of assays evaluating the direct effects of our 
anti-CD47 antibody on T cell activation. Previous reports have shown that CD47 
is highly expressed on the surface of T cells [55,84], and our data examining 
CD47 expression on the surface of naïve and activated OT-I T cells confirms 
these previous reports (Figure 3-3A). Anti-CD47 monoclonal antibodies have 
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been reported to have inhibitory or costimulatory effects on T cell activation 
depending on the antibody clone and the concentrations used [149]. Therefore, 
to ensure that T cell activation in our model system would result from 
macrophage antigen presentation and not from exposure to our anti-CD47 
monoclonal antibody (MIAP301), we performed a series of activation assays. We 
harvested OT-I T cells from transgenic mice and activated the cells in vitro in the 
presence or absence of MIAP301. We observed no change in the expression of 
T cell activation markers (CD69, CD44) in OT-I cells treated with MIAP301 
(Figures 3-3B and 3-3C), demonstrating that treatment with MIAP301 alone does 
not alter T cell activation. According to the blocking assays previously performed, 
the concentrations of MIAP301 used in this experiment were saturating and thus 
should have the greatest possible impact on T cell activation. This experiment 
was performed in vitro under ideal T cell activation conditions, and T cells 
activated in vivo will likely be exposed to lower levels of MIAP301. Therefore, any 
changes in we observed in T cell activation in vivo likely resulted from antigen 
presentation and not from direct antibody stimulation.  
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 Next, we performed a series of assays to evaluate whether CD47 
blockade could enhance antigen presentation and priming of antigen-specific T 
cells in vivo. We injected syngeneic Thy1.2 C57BL/6 mice subcutaneously with 
B16-OVA tumor cells. Once tumors were visibly established (9 days post tumor 
cell injection), the mice received two injections of PBS, the anti-CD47 antibody 
MIAP301, or an isotype control antibody (Figure 3-4). Two days after the second 
injection, we harvested OT-I and OT-II T cells from transgenic recipients, labeled 
the cells with the vital dye CellTraceTM Violet (CTV), and adoptively transferred 
the cells into tumor bearing mice. As a negative control, we adoptively 
transferred OT-I and OT-II T cells into a non-tumor bearing mouse to assess the 
basal level of T cell activation in vivo. As a positive control, we adoptively 
transferred OT-I and OT-II T cells into a tumor-bearing mouse along with an 
A B C 
Figure 3-3: CD47 blockade does not alter T cell activation in vitro. A. CD47 
expression on OT-I T cells. OT-I T cells were harvested and purified by magnetic 
enrichment. Cells were activated in vitro using Kb/B7, SIINFEKL peptide, and IL-12. 
Labeling of OT-I cells with the anti-CD47 mAb MIAP301 conjugated to PE was detected 
by flow cytometry. B. OT-I T cells were activated in vitro as described above in the 
presence of 10 µg/mL IgG2a or MIAP301. Three days following activation, cells were 
labeled with anti-mouse CD69 (APC) and anti-mouse CD44 (FITC) and expression was 
evaluated by flow cytometry.  
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injection of SIINFEKL peptide (recognized by OT-I cells) and OVA323-339 peptide 
(recognized by OT-II cells) to stimulate the cells. Three days after the adoptive 
transfer, we harvested T cells from the tumor, tumor-draining lymph node, and 
non-draining (contralateral) lymph node. Using flow cytometry, we identified OT-I 
and OT-II T cells by the congenic marker Thy1.1 and CTV labeling and assessed 
T cell activation by measuring CTV dye dilution, which marks the number of cell 
division cycles OT-I and OT-II cells underwent in vivo. Instances in which fewer 
than 100 OT-I or OT-II cells were collected from the lymph node or tumor were 
not included in the final analysis as it was not possible to assess CTV dye 
dilution accurately with low cell numbers.  
In the tumor draining lymph node (DLN), treatment with MIAP301 slightly 
increased the number of mice in which OT-I cells were activated and dividing, 
and the average percent division of the OT-I T cells increased from 24.5 ± 4.4% 
Figure 3-4: Schematic of the experimental design to assess the effects of CD47 
blockade on antigen-specific T cell activation in vivo 
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in the isotype control treated mice to 41.7 ± 10.2% in the MIAP301 treated mice 
(Figure 3-5A). We observed no change in the division of OT-I cells harvested 
from the non-draining (contralateral) lymph node (NDLN), which indicates that a 
tumor-specific response had occurred (Figure 3-5B). We observed a slight 
increase in the number of mice with activated OT-II T cells following treatment 
with MIAP301, and the percent division in the DLN increased slightly from 14.4 ± 
3.6% in the isotype control treated mice to 23.3 ±  7.7% in the MIAP301 treated 
mice (Figure 3-5C). However, we also observed an increase in the percent 
division of OT-II cells isolated from the NDLN, which may indicate that a systemic 
response, not a tumor-specific response, occurred (Figure 3-5D). It is also 
possible that the OT-II cells were activated during isolation and processing prior 
to being adoptively transferred. It is important to note that, for the NDLN, we 
recovered sufficient numbers of OT-II cells for analysis from only two mice per 
group; therefore, we may lack sufficient power to accurately gauge the OT-II 
response in this model system. We did not recover enough OT-I or OT-II T cells 
from the tumor to assess T cell responses in the tumor microenvironment, which 
may indicate that MIAP301 did not increase T cell trafficking to the tumor. It is 
unlikely that we did not adoptively transfer sufficient numbers of OT cells to 
detect their presence in the tumor, as the adoptive transfer protocol we used in 
this experiment has been successfully implemented for the study of intratumoral 
T cells [147]. Overall, these results suggest that treatment with MIAP301 leads to 
a slight increase in antigen-specific CD8+ T cell activation in the tumor DLN.   
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Figure 3-5: Activation of antigen-specific class I (OT-I) and class II (OT-II) T cells is 
enhanced by CD47 blockade. B16-OVA tumor bearing mice received injections of either 
PBS (no antibody), IgG2a isotype control antibody, or anti-CD47 monoclonal antibody 
(MIAP301) on days 10 and 12 following tumor cell inoculation (200µg IP/injection or 
equivalent volume of PBS). 1x106 OT-I and OT-II T cells were purified, labeled with Cell-
Trace Violet (CTV), and injected IV on day 14. Negative control: OT-I and OT-II T cells 
were injected into a non-tumor bearing mouse. Positive control: OT-I and OT-II T cells 
were injected into a tumor bearing mouse along with SIINFEKL peptide and OVA323-339 
peptide. On day 17, the tumor draining lymph node (DLN) and the contralateral, non-
draining lymph node (NDLN) of each mouse were harvested, and cells were analyzed by 
flow cytometry. Gating of OT-I and OT-II cells was performed using congenic markers and 
percent division was determined by CTV dye dilution. T cell activation was assessed if 
more than 100 OT cells were recovered. Each symbol represents a different mouse; 
assay was performed 3 times with 3 mice per experimental group and 1-2 mice per control 
group. A. Division of OT-I cells in the DLN. p=0.4975, Kruskal-Wallis test. B. Division of 
OT-I cells in the NDLN. p=0.6173, Kruskal-Wallis test. C. Division of OT-II cells in the 
DLN. p=0.4675, Kruskal-Wallis test. D. Division of OT-II cells in the NDLN. p=0.0667, 
Kruskal-Wallis test.  
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 To determine if the slight increase observed in antigen-specific CD8+ T 
cell activation in response to CD47 blockade was capable of mediating tumor 
rejection, we monitored B16-OVA tumor growth over the course of three weeks. 
Tumor-bearing C57BL/6 mice received three injections of the anti-CD47 antibody 
MIAP301 or an isotype control antibody (Figure 3-6). We adoptively transferred 
OT-I and OT-II T cells following antibody treatment as previously described. In 
addition, two groups received transfers of 5x106 OT-I and OT-II cells as a positive 
control, as it is known that this number of OT cells is capable of suppressing 
tumor growth (M. Mescher, unpublished data).  
In agreement with previous observations, increased numbers of OT-I and 
OT-II T cells (5x106 versus 1x106 cells) provided greater tumor control (Figure 3-
7), demonstrating that antigen-specific T cells are capable of controlling tumor 
growth in this model system. However, we observed no differences in tumor 
Figure 3-6: Schematic of the experimental design to assess the effects of CD47 
blockade on B16-OVA tumor growth 
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growth between the isotype control and MIAP301 treated animals (Figure 3-7). 
This result demonstrates that although CD47 blockade leads to a small increase 
in phagocytosis as well as OT-I and OT-II T cell activation, this increase is not 
therapeutically significant in the B16 melanoma model. Therefore, unlike 
previously studied model systems in which CD47 blockade induced tumor 
regression [64,66,75,83], B16 mouse melanoma appeared to be resistant to 
CD47 blockade therapy.  
 
 
 
 
 
Figure 3-7: CD47 blockade does not enhance antigen-specific rejection of B16-OVA 
melanoma tumors in vivo. B16-OVA tumor-bearing mice received IP injections of either 
IgG2a isotype control antibody or MIAP301 on days 13, 15, and 17 following tumor cell 
inoculation (200μg IP/injection). On day 17, OT-I and OT-II T cells were purified, labeled with 
cell trace violet (CTV), and injected intravenously. Groups received either 1.0x106 or 5.0x106 
of each OT-I and OT-II cells. Tumor growth was measured with calipers, and volume was 
calculated as length x width2 x 0.52. A. Graph represents a spider plot of tumor growth in 
individual mice.  B. Bar graph (mean ± SEM) representing tumor burden at the experimental 
endpoint (day 24 or maximum tumor volume). P=0.79 Kruskal-Wallis test.  
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Melanoma cell resistance to phagocytosis is evolutionarily conserved 
 To evaluate if melanoma cell resistance to phagocytosis was unique to 
mouse B16 cells, we examined the sensitivity of human and canine melanoma 
and lymphoma cells to macrophage-mediated phagocytosis. This multi-species 
approach allowed us to identify evolutionarily conserved mechanisms of 
immunoevasion that are necessary for melanoma cell survival. We first confirmed 
that human (M21) and canine (TLM1) melanoma cell lines express CD47 at 
levels comparable to human (Raji) and canine (CLBL1) lymphoma cells (Figure 
3-8A). The CD47 blocking reagent CV1-G4 has previously demonstrated efficacy 
in both the Raji [65] and CLBL1 [78] models, but it has not yet been tested in 
human or canine melanoma.  Therefore, we performed competition assays to 
validate the ability of this reagent to block CD47 on melanoma cells. In these 
assays, CV1-hIgG4 efficiently blocked interactions between anti-CD47 antibodies 
and CD47 expressed on the surface of human (Figure 3-8B) and canine (Figure 
3-8C) melanoma cells.  
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To compare the sensitivity of human and canine melanoma and 
lymphoma cells to phagocytosis, we performed a series of in vitro phagocytosis 
assays. As our group and others have previous shown [65,78], Raji and CLBL1 
lymphoma cells demonstrated sensitivity to phagocytosis (31.6 ± 2.9% and 50.3 
± 0.9% phagocytosis, respectively) that was further enhanced by the addition of 
CV1-hIgG4 (to 55.6 ± 3.3% and 80.0 ± 2.0%, respectively, Figure 3-9A-C). While 
we observed small increases in M21 and TLM1 melanoma cell phagocytosis in 
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Figure 3-8: CD47 Expression and blockade on human and canine tumor cell lines. 
A. CD47 expression on target cells. Labeling of human melanoma (M21) and lymphoma 
(Raji) cell lines and canine melanoma (TLM1) and lymphoma (CLBL1) cell lines with the 
anti-CD47 mAb 5F9 conjugated to Alexa 488 was detected by flow cytometry. B and C. 
Blockade of CD47 using CV1-G4. Human M21 melanoma cells (B) or canine TLM1 
melanoma cells (C) were incubated with unlabeled CV1-G4 at the indicated 
concentrations for 15 minutes, followed by subsequent labeling with Alexa-488 hu5F9 
mAb. The ability of the labeled antibody to bind CD47 on the cell surface was evaluated 
by flow cytometry (MFI).  
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response to CD47 blockade, the overall percent phagocytosis of these cells (3.7 
± 1.0% and 12.4 ± 2.0%, respectively) remained very low compared to lymphoma 
cells (Figure 3-9A-C). Based on the in vivo data we obtained with the B16 mouse 
melanoma model (Figures 3-5 and 3-7), it is likely that this increase in 
phagocytosis, while statistically significant, is not therapeutically significant. Thus, 
the resistance to phagocytosis that we observed in mouse melanoma cells 
seems to be conserved in melanoma cells across species.  
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Previous reports have demonstrated the therapeutic efficacy of CD47 
blockade against a number of solid tumor types [66,75]. To compare the 
phagocytosis of other solid tumors to melanoma cell phagocytosis, we performed 
additional in vitro phagocytosis assays using human, canine, feline, and mouse 
breast/mammary cancer cells as well as human, mouse, and canine 
C 
Figure 3-9: Melanoma cell resistance to phagocytosis is conserved across species. 
A. Phagocytosis of human tumor cells. CFSE-labeled tumor cells were incubated with J774 
macrophages in the presence of control IgG4 or CV1-G4. Phagocytosis was quantified as 
the percent of F4/80+ J774 cells that engulfed CFSE+ tumor cells per total F4/80+ 
population. Flow cytometry plots representing the mean percent phagocytosis are shown B. 
Phagocytosis of canine tumor cells as described in A. C. Quantification of phagocytosis 
assays. Bars represent 3 experiments (CLBL1 p=0.0078, TLM1 p=0.0985), 12 experiments 
(M21, p=0.0076), or 16 experiments (Raji, p<0.0001) repeated in triplicate (mean± SEM). P 
values were determined by Kruskal-Wallis test or one-way ANOVA.  
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osteosarcoma cells. Breast cancer and osteosarcoma cells displayed lower basal 
levels of phagocytosis (10.5 ± 1.0% and 15.6 ± 1.3%, respectively) than 
lymphoma cells but remained more sensitive to phagocytosis than melanoma 
cells (Figure 3-10A-B). In contrast to melanoma cells, both cell types exhibited a 
substantial increase in phagocytosis (to 31.2 ± 2.6% and 25.8 ± 2.1%, 
respectively) in response to CD47 blockade (Figure 3-10A-B). We observed 
similar results while performing phagocytosis assays with a human colon 
adenocarcinoma and a mouse lung adenocarcinoma cell line (data not shown). 
Therefore, melanoma resistance to phagocytosis appears to be unique, at least 
as compared to lymphoma and the other solid tumors tested (Figure 3-10C).   
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Conclusions: In this chapter, we evaluated the susceptibility of mouse, human, 
and canine melanoma cells to phagocytosis mediated by CD47 blockade. We 
confirmed the expression of CD47 on the surface of melanoma cell lines and 
validated the ability of a SIRPa mimotope, CV1-G4, and an anti-CD47 
A B 
Figure 3-10: Melanoma resistance to phagocytosis is unique compared to other 
solid tumors. CFSE-labeled tumor cells were incubated with J774 macrophages in 
the presence of control IgG4 or CV1-G4. Phagocytosis was quantified as the percent 
of F4/80+ J774 cells that engulfed CFSE+ tumor cells per total F4/80+ population. Bars 
represent two experiments were performed in triplicate (mean ± SEM). A. 
Phagocytosis of human (MCF7), mouse (4T1), canine (CMT12), and feline (K12) 
breast cancer cells. p<0.005 for all cell lines by Kruskal-Wallis test B. Phagocytosis of 
human (SAOS2), mouse (K12 mOS), and canine (OSCA40 and OSCA78) 
osteosarcoma cells. p<0.05 for SAOS2, OSCA40, OSCA78. p=0.1393 for K12 mOS 
by Kruskal-Wallis test. C. Summary of phagocytosis assays for all species tested. 
p<0.0001 by one-way ANOVA. 
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monoclonal antibody, MIAP301, to block the CD47-SIRPa axis on these cells. 
Our data demonstrate that melanoma cells display a resistance to phagocytosis 
that is not seen in lymphoma, breast cancer, or osteosarcoma cells and cannot 
be fully mitigated by CD47 blockade. In addition, CD47 blockade failed to prime 
an anti-tumor adaptive immune response or mediate tumor regression in an 
antigen-specific model of mouse melanoma. The conservation of this resistance 
in melanoma cells from three species suggests that this mechanism may be 
necessary for tumor cell immunoevasion and survival. In the next chapter, we will 
investigate whether modulation of pro-phagocytic signals in addition to CD47 
blockade can overcome melanoma resistance to phagocytosis.  
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Chapter 4 
 
Modulation of known phagocytic signals cannot 
overcome melanoma resistance to phagocytosis 
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Rationale and Objective: Phagocytosis relies on a balance of pro-phagocytic 
(“eat me”) and anti-phagocytic (“don’t eat me”) signals expressed on the surface 
of target cells [48]. Pro-phagocytic signals, such as phosphatidylserine (PS) and 
calreticulin (CRT), are expressed on the surface of cells undergoing 
immunogenic cell death and can be induced by treatment with chemotherapy 
drugs in the anthracycline class, such as doxorubicin [48,53]. Previous reports 
have indicated that CRT expression is necessary for tumor cell phagocytosis and 
for a form of immunogenic cell death that leads to an anti-tumor immune 
response [52,53]. Our objective in this chapter was to evaluate whether 
increasing pro-phagocytic signals in combination with CD47 blockade could 
enhance melanoma cell phagocytosis and activation of a tumor-specific T cell 
response. 
 
Results 
Modulation of pro-phagocytic signals fails to enhance the phagocytosis of 
melanoma cells 
Previous reports have demonstrated that anthracycline chemotherapies, 
including the drug doxorubicin, induce rapid translocation of the “eat me” signal 
calreticulin (CRT) to the surface of colon cancer cells, but the effects of 
chemotherapy on pro-phagocytic signal expression in melanoma cells is currently 
unknown. Melanoma cells are notoriously resistance to chemotherapy-induced 
apoptosis both in vitro and in vivo  [150]. Therefore, we investigated whether low-
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dose doxorubicin chemotherapy could induce “eat me” signal expression and 
enhance the anti-tumor immune response in the absence of cell death. To 
optimize the dose of doxorubicin chemotherapy used, we treated B16-OVA 
melanoma cells with increasing concentrations of doxorubicin and quantified cell 
viability at 24, 48, and 72 hours using the colorimetric MTS assay. We 
determined that treatment with 0.03µM doxorubicin for 24 hours did not alter cell 
viability compared to untreated cells (Figure 4-1A). We then demonstrated that 
this dose of doxorubicin chemotherapy was capable of inducing PS exposure 
and CRT expression in the treated cells without loss of membrane integrity 
(Figures 4-1B-C).  
To investigate whether the induction of pro-phagocytic signals would 
synergize with CD47 blockade to enhance melanoma cell phagocytosis in vitro, 
we placed doxorubicin-treated B16 cells in a phagocytosis assay with mouse 
macrophages in the presence or absence of CV1-hIgG4. We observed no 
difference in phagocytosis following doxorubicin treatment alone or in 
combination with CD47 blockade (Figure 4-1D).  
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A B 
Figure 4-1: Upregulation of “eat me” signals following chemotherapeutic treatment 
fails to enhances the phagocytosis of B16-OVA cells. A. B16-OVA cells were cultured in 
96 well plates with the indicated doses of doxorubicin chemotherapy. Cell viability was 
assessed at 24, 48, and 72 hours using the MTS assay. B-D. B16-OVA tumor cells were 
treated for 24 hours with 0.03μM doxorubicin chemotherapy or PBS. B. Phosphatidylserine 
(PS) exposure following doxorubicin treatment. Display of membrane PS was evaluated by 
flow cytometry and is represented by the %Annexin V+Propidium Iodide- cells. B. 
Calreticulin (CRT) exposure following doxorubicin treatment. Cells were labeled with an 
anti-mouse CRT antibody (Alexa Fluor 647) and analyzed by flow cytometry. C. 
Phagocytosis of doxorubicin treated cells. Treated cells were incubated with J774 
macrophages in the presence of control IgG4 or CV1-G4. Phagocytosis was quantified as 
the percent of F4/80+ J774 cells that engulfed GFP+ tumor cells per total F4/80+ population. 
Bars represent 3 experiments were performed in triplicate (mean ± SEM) p=0.3089, one-
way ANOVA. Positive control p=0.0082, 2-tailed t-test.  
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Combining a tumor cell-specific monoclonal antibody with CD47 blockade 
has also been shown to enhance phagocytosis by providing a pro-phagocytic 
stimulus through the Fc receptor [68,78]. To investigate whether this pro-
phagocytic stimulus could promote the phagocytosis of melanoma cells, we 
utilized a monoclonal antibody targeting the neural stem cell marker CD271 [88]. 
We confirmed CD271 expression on the surface of human M21 melanoma cells 
(Figure 4-2A). However, we found that combining CD47 blockade with an anti-
CD271 antibody failed to enhance the phagocytosis of M21 melanoma cells 
(Figure 4-2B). Overall, these results demonstrate that modulation of pro-
Figure 4-2: Addition of a tumor-specific antibody fails to enhance CD47 
mediated phagocytosis of melanoma cells. A. CD271 expression on human 
melanoma cells. Labeling of human melanoma (M21-GFP) cells with an anti-
CD271 antibody conjugated to Alexa Fluor 647 was detected by flow cytometry. B. 
M21-GFP tumor cells were incubated with J774 macrophages in the presence of 
control huIgG4, CV1-G4, anti-CD271, or a combination of antibodies. Phagocytosis 
was quantified as the percent of F4/80+ J774 cells that engulfed CFSE+ tumor cells 
per total F4/80+ population. Experiments were performed in triplicate and repeated 
twice. Bars represent mean ± SEM. p>0.05 for all M21 conditions, Mann-Whitney 
test.  
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phagocytic signals in combination with CD47 blockade cannot overcome 
melanoma cell resistance to phagocytosis.  
 
Combination doxorubicin chemotherapy and CD47 blockade fail to 
enhance tumor-specific T cell activation  
Although traditionally thought to be immunosuppressive, accumulating 
evidence indicates that several types of chemotherapy, including doxorubicin, are 
capable of promoting anti-tumor immune responses. Doxorubicin has been 
shown to promote type I interferon signaling, the influx of myeloid and lymphoid 
cells into mouse tumors, and dendritic cell maturation [151]. Therefore, 
doxorubicin affects multiple immune cells in the tumor microenvironment, and, 
although we did not observe an increase in phagocytosis in vitro following 
combination doxorubicin and CD47 blockade therapy, it was possible that these 
agents would synergize to activate an adaptive anti-tumor immune response.  
To test whether combination chemo-immunotherapy is capable of 
activating T cells in vitro, we again utilized B16-OVA melanoma cells and OT-
I/OT-II antigen specific T cells (see Chapter 3 for a description of this model 
antigen system). B16-OVA cells were treated with PBS or doxorubicin 
chemotherapy at the dose optimized previously (Figure 4-1). We then performed 
a phagocytosis assay in which B16-OVA cells were cultured with primary bone 
marrow-derived mouse macrophages in the presence or absence of CD47 
blockade (Figure 4-3). Following the assay, we verified that phagocytosis had 
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occurred and isolated the macrophage population by magnetic separation. 
Macrophage purity was consistent between the treatment groups (60-80%). We 
then incubated the purified macrophages with OT-I and OT-II T cells at a 0.1:1, 
0.25:1, 0.5:1, or 1:1 macrophage: T cell ratio to allow antigen presentation to 
occur. At 24, 48, 72, and 96 hours of incubation, supernatant was collected from 
each well and analyzed for IFNg and IL-2 production by ELISA. At 72 hours, we 
analyzed expression of the T cell activation markers CD44 and CD69 by flow 
cytometry. Negative controls included macrophages alone, naïve OT-I and OT-II 
T cells cultured alone, and naïve T cells cultured with macrophages that had not 
been placed in a phagocytosis assay. T cells activated in vitro using Kb/B7, 
SIINFEKL and OVA 323-339 peptides, and IL-12 served as a positive control.  
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In general, higher macrophage to T cell ratios induced greater T cell 
activation as measured by expression of the activation markers CD69 and CD44.  
However, we saw no consistent differences in CD69 or CD44 expression 
between the treatment groups (Figure 4-4A-B). Overall, cytokine production as 
detected by ELISA was very low for all the treatment groups tested. We detected 
B16-
OVA 
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Doxorubicin 
24 hours 
Phagocytosis 
assay +/- CD47 
blockade 
2 hours 
Purify macrophages 
by magnetic 
separation 
Incubate with 
OT-I and OT-II T 
cells at varying 
ratios 
Harvest 
supernatant 
at 24, 48, 72, 
96 hrs 
Run IL-2 
and IFN-y 
ELISAs 
Verify phagocytosis 
by flow cytometry 
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FSC-A
0
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100K
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200K
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SS
C
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0 102 103 104 105
eGFP-A
0
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y7
-A
84.3
Verify purity by 
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Figure 4-3: Schematic of experimental design to assess the effects of 
doxorubicin chemotherapy and CD47 blockade on in vitro T cell activation.  
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no IL-2 production by ELISA at 24 hours, and we observed no differences in IL-2 
production between the treatment groups at 48, 72, or 96 hours (Figure 4-4C). 
IFNg production was only detected at 72 hours in wells cultured with a 0.5:1 
macrophage to T cell ratio; again, we observed no differences in IFNg production 
between the groups (Figure 4-4D). Based on the low cytokine production, it 
appears that the OT-I and OT-II T cells were poorly activated by the 
macrophages in this assay. B16-OVA cells are poorly phagocytosed by 
macrophages (Figure 3-2), which may lead to suboptimal levels of macrophage 
antigen presentation or cytokine production and therefore reduced T cell 
activation in this assay. Low levels of T cell activation could also be a result of 
the in vitro activation conditions; however, previous reports have demonstrated 
successful in vitro activation of OT T cells in a similar assay [152]. Overall, 
combination doxorubicin chemotherapy and CD47 blockade were unable to 
increase antigen specific T cell activation in vitro.  
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One limitation of in vitro assays is the lack of a normal tumor 
microenvironment and immune system components. In addition to stimulating 
macrophage phagocytosis, CD47 blockade has been shown to increase dendritic 
cell phagocytosis and antigen presentation [83] and may enhance neutrophil-
mediated antibody dependent cellular cytotoxicity [80]. Doxorubicin, as previously 
mentioned, has also been shown to stimulate activation of other immune 
components, including dendritic cells [151]. Therefore, despite the fact that 
combination doxorubicin chemotherapy and CD47 blockade did not enhance 
antigen-specific T cell activation in vitro, we tested whether this combination 
chemo-immunotherapy would have an effect on melanoma tumor growth in vivo. 
We injected syngeneic Thy1.2 C57BL/6 mice subcutaneously with B16-OVA 
tumor cells. Once tumors were visibly established (10 days post tumor cell 
injection), the mice received two injections of the anti-CD47 antibody MIAP301 or 
an isotype control antibody (Figure 4-5). In addition, mice received one injection 
of 5 mg/kg doxorubicin or an equivalent amount of PBS. Four to six hours after 
the second antibody injection, we harvested OT-I T cells from transgenic 
recipients, labeled the cells with the vital dye CellTraceTM Violet (CTV), and 
adoptively transferred the cells into tumor bearing mice. As a negative control, 
we adoptively transferred OT-I cells into a non-tumor bearing mouse to assess 
the basal level of T cell activation in vivo. As a positive control, we adoptively 
transferred OT-I cells into a tumor-bearing mouse along with an injection of 
SIINFEKL peptide to stimulate the cells. Three days after the adoptive transfer, 
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we harvested T cells from the tumor, tumor-draining lymph node (DLN), and non-
draining (contralateral) lymph node (NDLN). Using flow cytometry, we identified 
OT-I cells (CD45.1+CTV+CD8+Thy1.1+) and assessed T cell activation by 
measuring CTV dye dilution, which marks the number of cell division cycles OT-I 
cells underwent in vivo. 
 
None of the four treatment groups increased the percent division of OT-I T 
cells in the DLN, NDLN, or tumor (Figure 4-6). In addition, none of the four 
treatments increased the division index, which is the average number of cell 
divisions that a cell in the original population has undergone, in the DLN or 
NDLN. The division index for OT-I cells within the tumor could not be calculated 
as we did not recover enough cells for the algorithm to accurately assess the 
number of cell divisions (Figure 4-6). Percent division and the division index were 
+ 2x105 
B16-OVA 
cells SC 
10 days 
(visible 
tumor) 200 μg CD47 
or IgG IP +  
5 mg/kg 
doxorubicin  
or PBS 
2 days 200 μg 
CD47 or 
IgG IP 
1x106 OT-I 
(labeled with 
CTV) IV 
3 days 
Harvest LNs 
and tumor. 
Measure CTV 
dilution 
4-6 hours 
Figure 4-5: Schematic of the experimental design to assess the effects of CD47 
blockade and doxorubicin chemotherapy on antigen-specific T cell activation in vivo 
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decreased in the NDLN (average of 36.5 ± 4.9% division for all groups combined) 
as compared to the DLN (average of 56.4 ± 6.2% division) or tumor (average of 
79.7 ± 3.5% division), which indicates that a tumor-specific response occurred in 
the system. Treatment with MIAP301 alone lead to a slight increase in CD44 
expression in the tumor; however, we observed no change in CD44 expression in 
the DLN and no change in CD69 expression with MIAP301 treatment (Figure 4-
6). No other changes were observed in CD44 or CD69 expression levels. 
Therefore, combination doxorubicin chemotherapy and CD47 blockade does not 
lead to an increase in T cell activation in the B16 melanoma model.   
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Figure 4-6: Combination doxorubicin chemotherapy and CD47 blockade does not 
enhance the activation of antigen-specific T cells in vivo. B16-OVA tumor bearing 
mice received an injection of doxorubicin chemotherapy (5mg/kg IP) or an equivalent dose 
of PBS on day 10 following tumor injection. Groups also received injections of an isotype 
control antibody or an anti-CD47 antibody (MIAP301 clone) on days 10 and 12 (200µg 
IP/injection). 1E6
 
OT-I T cells were purified, labeled with cell trace violet (CTV), and 
injected IV on day 12. On day 15, the draining lymph node (DLN), non-draining lymph 
node (NDLN), and tumor of each mouse were harvested and cells were analyzed using 
flow cytometry. Gating of OT-I cells was performed using congenic cell markers, and 
division was determined by CTV dilution using proliferation modeling in Flowjo. Activation 
markers were assessed by labeling the cells with PE anti-mouse CD69 and FITC anti-
mouse CD44. Samples containing fewer than 100 OT-I cells were excluded from the final 
analysis. p>0.05 for all treatment groups and parameters, Kruskal-Wallis test.  
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Previous reports have indicated that endothelial CD47 may be required for 
T cell transendothelial migration [153,154]. As other reports have demonstrated 
effective T cell activation and tumor clearance following CD47 blockade [75,83], it 
is unlikely that CD47 blocking reagents inhibit T cell migration in vivo. However, 
to ensure that treatment with MIAP301 did not alter trafficking of OT-I T cells in 
our model system, we examined the absolute number of OT-I cells recovered 
from the DLN, NDLN, and tumor. As the percent division of OT-I cells was 
unchanged between the groups, any alterations in T cell number should 
represent a change in T cell trafficking in this system. We observed no change in 
the number of OT-I T cells in the DLN or NDLN between the groups (Figure 4-
7A-B). Treatment with MIAP301 alone lead to a slight increase in the number of 
intratumoral OT-I T cells (Figure 4-7C), which may indicate that MIAP301 
increases trafficking of OT-I cells to the tumor. However, we did not observe an 
increase in OT-I cell number in the tumors of mice treated with combination 
doxorubicin chemotherapy and MIAP301 (Figure 4-7C). Overall, we conclude 
that CD47 blockade with MIAP301 does not inhibit T cell migration in our model 
system.   
  
91 
Although the antigen-specific T cell response was not affected by 
combination doxorubicin chemotherapy and CD47 blockade, it was possible that 
the endogenous T cell response was altered by these treatments. The use of 
immunoreplete C57BL/6 mice made it possible for us to examine the expression 
of the T cell activation markers CD44 and CD69 on endogenous CD8+ and CD4+ 
T cells recovered from the DLN, NDLN, and tumor. Treatment with doxorubicin 
and/or CD47 blockade did not alter the number of CD8+ or CD4+ T cells in the 
DLN, NDLN, or tumor (Figure 4-8A). In general, intratumoral CD8+ T cells were 
more activated than CD8+ T cells in the DLN or NDLN, as measured by 
expression of the activation markers CD44 and CD69 (Figures 4-8B-C).   
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Figure 4-7: Effects of combination doxorubicin chemotherapy and CD47 blockade on 
antigen-specific T cell numbers. B16-OVA tumor bearing mice received an injection of 
doxorubicin chemotherapy (5mg/kg IP) or an equivalent dose of PBS on day 10 following 
tumor injection. Groups also received injections of an isotype control antibody or an anti-
CD47 antibody (MIAP301) on days 10 and 12 following tumor cell inoculation (200µg 
IP/injection). 1E6
 
OT-I T cells were purified, labeled with cell trace violet (CTV), and 
injected IV on day 12. On day 15, the draining lymph node (DLN), non-draining lymph node 
(NDLN), and tumor of each mouse were harvested and cells were analyzed using flow 
cytometry. Gating of OT-I cells was performed using congenic cell markers, and the 
number of OT-I T cells was normalized to 1E6 total lymphocytes. p>0.05 for all treatment 
groups in all locations, Kruskal-Wallis test.  
 
A B C 
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However, we did not observe any changes in CD8+ or CD4+ T cell activation 
status between the treatment groups (Figures 4-8B-C). We also did not observe 
an increase in CD44 or CD69 expression in CD8+ or CD4+ T cells harvested from 
the positive control mouse. In this experiment, injection of SIINFEKL peptide, 
recognized by OT-I cells, served as the positive control for OT-I activation. 
Exposure to SIINFEKL should not impact endogenous T cell activation, and 
therefore, this result was expected. We concluded that combination doxorubicin 
and CD47 blockade did not increase activation of endogenous CD8+ or CD4+ T 
cells.  
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Figure 4-8: Combination doxorubicin and CD47 blockade does not enhance 
endogenous CD8+ or CD4+ T cell activation. B16-OVA tumor bearing mice received an 
injection of doxorubicin chemotherapy (5mg/kg IP) or an equivalent dose of PBS on day 
10 following tumor injection. Groups also received injections of an isotype control antibody 
or an anti-CD47 antibody (MIAP301 clone) on days 10 and 12 following tumor cell 
inoculation (200µg IP/injection). On day 15, the draining lymph node (DLN), non-draining 
lymph node (NDLN), and tumor of each mouse were harvested and cells were analyzed 
using flow cytometry. Cell populations were labeled using PerCP-Cy5 anti-mouse CD8 
and APC eFluor 780 anti-mouse CD4. Activation markers were assessed by labeling the 
cells with PE anti-mouse CD69 and FITC anti-mouse CD44. p>0.05 for all treatment 
groups and parameters, Kruskal-Wallis test.  
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Conclusions: In this chapter, we investigated whether upregulation of pro-
phagocytic signals in combination with CD47 blockade could enhance melanoma 
cell phagocytosis and activation of a tumor-specific T cell response. We 
demonstrated that low-dose doxorubicin chemotherapy was capable of 
upregulating expression of the pro-phagocytic signals calreticulin and 
phosphatidylserine on the surface of mouse melanoma cells without altering 
membrane integrity. However, combination doxorubicin and CD47 blockade 
failed to increase melanoma cell phagocytosis in vitro. In addition to increasing 
pro-phagocytic signals through low-dose chemotherapy, we utilized a tumor-
specific antibody targeting the melanoma antigen CD271 to provide a pro-
phagocytic signal through the Fc receptor. Combination CD271 and CD47 
antibody therapy again failed to enhance melanoma cell phagocytosis. In both in 
vitro and in vivo T cell activation assays, combination doxorubicin chemotherapy 
and CD47 blockade failed to enhance antigen-specific T cell activation. 
Therefore, melanoma cells appear resistant to modulation of known pro-
phagocytic and anti-phagocytic signals. In the next chapter, we will explore the 
possibility that melanoma cells secrete or express additional, uncharacterized 
anti-phagocytic signals that protect the cells from phagocytosis by the innate 
immune system.  
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Chapter 5 
 
Investigation of the mechanisms underlying 
melanoma cell resistance to phagocytosis 
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Rationale and Hypothesis: In chapters 1 and 2, we demonstrated that 
melanoma cells from humans, dogs, and mice are exceptionally resistant to 
macrophage-mediated phagocytosis, and that this resistance cannot be 
overcome by modulation of known pro-phagocytic and anti-phagocytic signals. In 
this chapter, we hypothesize that melanoma cells possess an uncharacterized 
mechanism of resistance to phagocytosis, such as expression of a soluble or 
membrane bound “don’t eat me” signal. 
 
Results 
Secretion of soluble “don’t eat me” signals is not responsible for 
melanoma cell resistance to phagocytosis 
We first tested the hypothesis that melanoma cell resistance to 
phagocytosis was mediated by a secreted anti-phagocytic factor. As we 
previously showed that lymphoma cells are sensitive to macrophage-mediated 
phagocytosis (Chapter 3, [65,83]), we designed a series of experiments to test if 
a factor secreted by melanoma cells was capable of inhibiting phagocytosis of 
lymphoma cells. We incubated human Raji lymphoma cells with varying 
concentrations of culture supernatants from human M21 melanoma cells and 
examined the phagocytosis of the lymphoma cells by flow cytometry. We 
observed no inhibition of lymphoma cell phagocytosis or of the response to CD47 
blockade in the presence of melanoma cell supernatants (Figure 5-1A).  
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We next performed phagocytosis assays in which mouse macrophages 
were co-incubated with both Raji lymphoma cells (labeled with CFSE) and M21 
melanoma cells (labeled with CTV) at varying lymphoma cell to melanoma cell 
ratios. Macrophages in this assay preferentially phagocytized lymphoma cells as 
compared to melanoma cells (Figure 5-1B,C). Intriguingly, melanoma cell 
phagocytosis in this assay appeared to be increased compared to the levels of 
melanoma cell phagocytosis seen in previous assays (Chapter 3). We needed to 
exclude the possibility that this result was an artifact of the way data were 
quantified: in this experiment, we accounted for the variation in the number of 
tumor cells present between the conditions and therefore quantified phagocytosis 
as a percent of total tumor cells, rather than as a percent of total macrophages 
as was done previously. The different quantification methods could alter the 
absolute measure of phagocytosis. However, it is also possible that the Raji 
lymphoma cells secrete a pro-phagocytic factor that sensitized melanoma cells to 
phagocytosis. To distinguish between these two possibilities, we incubated M21 
melanoma cells with varying concentrations of culture supernatants from Raji 
lymphoma cells and analyzed M21 cell phagocytosis. Phagocytosis of M21 cells 
was extremely low in these experiments, despite the presence of Raji cell 
supernatant (1.25 ± 0.35% phagocytosis in the presence of new medium vs. 2.2 
± 0.12% phagocytosis in the presence of Raji cell supernatant, Figure 5-1D). 
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Therefore, we concluded that neither M21 cell supernatants or Raji cell 
supernatants affect macrophage-mediated phagocytosis in vitro.   
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Figure 5-1: Culture supernatants from melanoma or lymphoma cells do not alter 
tumor cell phagocytosis. A. Effects of melanoma supernatant on lymphoma cell 
phagocytosis. CFSE-labeled human lymphoma (Raji) cells were incubated with J774 
macrophages while suspended in supernatant harvested from cultured M21 melanoma 
cells and titrated with new IMDM medium. Phagocytosis was quantified as the percent of 
F4/80+ J774 cells that engulfed CFSE+ tumor cells per total F4/80+ population. Bars 
show one representative experiment (of three performed) repeated in triplicate (mean± 
SEM). p= 0.8471 based on two-way ANOVA. B. Effects of co-culturing melanoma cells 
and lymphoma cells on macrophage phagocytosis of tumor cells. CFSE-labeled Raji 
lymphoma cells were incubated with CTV-labeled M21 melanoma cells at varying ratios 
and placed in a phagocytosis assay as described. Phagocytosis was quantified as the 
percent of F4/80+ J774 cells that engulfed CFSE+ or CTV+ tumor cells per total CFSE+ 
or CTV+ population. Flow cytometry plots representing the mean percent phagocytosis 
are shown. C. Quantification of phagocytosis assays. Bars show one representative 
experiment (of two performed) repeated in duplicate (mean± SEM). p=0.3722 (Raji) or 
p=0.1506 (M21), Two-way ANOVA. D. Effects of lymphoma supernatant on melanoma 
cell phagocytosis. The experiment described in panel A was repeated using CFSE-
labeled human M21 melanoma cells suspended in supernatant harvested from cultured 
Raji lymphoma cells. Bars show one representative experiment (of two performed) 
repeated in triplicate (mean± SEM). p<0.001, two-way ANOVA. 
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To address the possibility that melanoma cells secrete a locally acting or 
short lived anti-phagocytic factor that is not transferred in cell culture 
supernatants, we treated M21 melanoma cells with the secretory inhibitor, 
Brefeldin A (BFA).  BFA causes the rapid, reversible dissociation of ADP-
ribosylation factor (ARF) from the Golgi complex, which in turn prevents the 
assembly and budding of secretory vesicles [155]. We first determined that two-
hour treatment with 5.0 µg/mL BFA did not significantly increase M21 cell death 
compared to untreated cells (Figure 5-2A). In control assays, we observed no 
defect in the phagocytosis of BFA treated Raji cells (Figure 5-2B), which 
indicates that BFA treatment does not negatively affect macrophage 
phagocytosis. Similarly, BFA treatment did not enhance phagocytosis of 
melanoma cells in this system (Figure 5-2B). Together, these results indicate that 
a secreted factor is not responsible for melanoma cell resistance to 
phagocytosis.  
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Melanoma resistance to phagocytosis cannot be overcome by knockdown 
of 47 membrane-bound proteins with the potential to deliver “don’t eat me” 
signals 
To investigate the role of other membrane bound proteins with the 
potential to deliver “don’t eat me” signals as mediators of melanoma cell 
resistance to phagocytosis, we used gene expression data and published reports 
in the scientific literature (obtained through PubMed) to identify candidate 
proteins that were selectively expressed on the surface of melanoma cells as 
compared to lymphoma, colon cancer, lung cancer, or breast cancer cells. We 
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Figure 5-2: Inhibiting secretion does not improve melanoma cell phagocytosis A. 
Effects of Brefeldin A (BFA) treatment on melanoma cell viability. Human M21 melanoma 
cells were treated with 5.0 µg/mL BFA. Cell viability was assessed at varying time points 
by flow cytometry. Cell death was measured as the percent propidium iodide (PI) positive 
cells. B. Effect of Brefeldin A (BFA) treatment on phagocytosis. M21-GFP or CFSE+ Raji 
cells were pretreated with 5.0 µg/mL BFA for 2 hours prior to co-culture with J774 
macrophages in the presence control IgG4 or CV1-G4. Phagocytosis was analyzed by 
flow cytometry as in Figure 5-1a. Bars represent two experiments repeated in triplicate 
(mean± SEM). p=0.2509 (Raji); p<0.001 (M21) by one-way ANOVA.  
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utilized data from The Cancer Genome Atlas Research Network (TCGA, 
http://cancergenome.nih.gov/) to compare gene expression in cutaneous 
melanoma samples to gene expression in cancers that have demonstrated 
sensitivity to CD47 blockade, including lymphoma [52], breast cancer [66], colon 
adenocarcinoma [66,75], lung adenocarcinoma [156], and lung squamous cell 
carcinoma [157] (See also figure 3-10C). Through this analysis, we identified a 
unique cluster of genes encoding plasma membrane proteins that were highly 
expressed in melanoma cells (Figure 5-3).  
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Figure 5-3: Heatmap of the top 500 most variable extracellular genes from a 
subset of TCGA cancer types. Clustering was performed based on gene expression 
in transcripts per million (by rows). Gene expression values are centered and scaled.  
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We also searched the PubMed literature database for proteins expressed 
on the surface of melanoma cells. Proteins were chosen based on one of four 
criteria: (1) the gene or protein had been identified as a “don’t eat me” signal in 
the literature, (2) expression of the gene or protein was restricted to, or 
expressed almost exclusively by, melanoma cells, increasing the likelihood that it 
might be responsible for melanoma-specific resistance to phagocytosis, (3) the 
gene or protein was shown to contribute to melanoma cell growth and metastasis 
(as evasion of phagocytosis is likely important to cell survival, particularly during 
metastasis), or (4) the gene or protein was associated with immune suppression 
in the tumor microenvironment. Based on the gene expression data and literature 
reports, we developed a siRNA panel targeting 47 genes encoding proteins that 
are expressed on the plasma membrane (Table 5-1). In addition, we utilized a 
control siRNA targeting Bcl-2, which we expected to sensitize the melanoma 
cells to apoptosis. siRNAs allow for rapidly, efficient, target-specific gene 
knockout without a prolonged cell selection period, which makes siRNAs ideal for 
large-scale screens [158]. In addition, siRNA function is not dependent on Dicer 
and other molecules of the microRNA processing pathway, which may be 
downregulated in cancer [158,159]. Although siRNA mediated knockdown is 
transient, it should have been sufficient for these assays, in which we only 
required gene knockdown to persist for the course of phagocytosis assay.  
 
 
  
105 
 
Assigned	
Number	
Gene	
Symbol	
Assigned	
Number	
Gene	
Symbol	
1	 BCL2	 25	 JAM3	
2	 CD200	 26	 ITGAV	
3	 PECAM1	 27	 ITGA2	
4	 CD151	 28	 ITGA3	
5	 CD81	 29	 ITGA4	
6	 SERPINE1	 30	 ITGA5	
7	 ANXA1	 31	 ITGA6	
8	 MIF	 32	 ITGA7	
9	 SELPLG	 33	 ITGB1	
10	 ECM1	 34	 ITGB3	
11	 CDH1	 35	 ITGB4	
12	 CDH2	 36	 ITGB5	
13	 CDH3	 37	 ICAM1	
14	 CLDN1	 38	 AGER	
15	 CLDN12	 39	 LGALS1	
16	 ALCAM	 40	 LGALS3	
17	 MCAM	 41	 DSC3	
18	 NCAM1	 42	 CAV1	
19	 CEACAM1	 43	 ST8SIA1	
20	 BCAM	 44	 MLANA	
21	 L1CAM	 45	 PMEL	
22	 MADCAM1	 46	 TRPC1	
23	 EPCAM	 47	 MFGE8	
24	 F11R	 48	 PXN	
 
Prior to testing the siRNA panel, we optimized transfection of M21-GFP 
human melanoma cells using a reporter siRNA, siGLO Red Transfection 
Indicator (Figure 5-4A). We verified that transfection with a CD47-targeting 
siRNA reduced expression of surface CD47 by 40-60% (Figure 5-4B) and that 
transfection of an av integrin-targeting siRNA reduced expression of surface av 
Table 5-1: Targets of the cell surface siRNA panel 
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integrin by 60-65% (Figure 5-4C). Expression level varied among the cells due to 
the transient nature of siRNA knockdown, as siRNAs are not replicated during 
cell division. We utilized a random number generator to select seven genes from 
the panel and evaluated their expression as well as CD47 expression by 
quantitative real-time PCR. The results showed a 75-90% reduction in mRNA 
expression of these proteins following siRNA-mediated knockdown (Figure 5-
4D). We concluded that, as predicted, the siRNAs utilized in this experiment 
efficiently reduced gene expression in human melanoma cells.   
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Figure 5-4: Optimization of M21-GFP transfection with siRNA reagents. A. Fluorescent 
microscopy images of M21-GFP cells 48 hours following transfection with 100 nM non-
targeting siRNA (siCTRL) or 100 nM siGLO-RFP. B. CD47 expression of parental M21-
GFP cells and cells transfected with siCD47 was evaluated by flow cytometry 48 hours after 
transfection. C. avb3 integrin expression of parental M21-GFP cells and cells transfected 
with siav integrin was evaluated by flow cytometry 48 hours after transfection. 
D. Expression levels of eight target genes were evaluated by quantitative RT-PCR 48 hours 
after transfection with siRNA. Gene expression was normalized to GAPDH among samples. 
Bars represent three transfections (mean± SEM).  
 
D 
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To address the possibility that a combination of cell surface proteins, 
rather than one individual protein, were acting as an anti-phagocytic signal, we 
utilized a random number generator to combine the 48 siRNAs into pools of three 
siRNAs plus a siRNA targeting CD47. Each siRNA was used in four different 
pools to evaluate the effects of different siRNA combinations or to identify any 
siRNA that consistently affected melanoma cell phagocytosis (Table 5-2).   
Group 1 Group 2 Group 3 Group 4 
Pool siRNA 
Numbers 
Pool siRNA 
Numbers 
Pool siRNA 
Numbers 
Pool siRNA 
Numbers 
Pool 1 34, 5, 42 Pool 1 12, 37, 44 Pool 1 26, 35, 48 Pool 1 1, 45, 19 
Pool 2 21, 38, 20 Pool 2 43, 4, 21 Pool 2 14, 41, 29 Pool 2 34, 30, 46 
Pool 3 13, 31, 2 Pool 3 8, 35, 18 Pool 3 20, 28, 44 Pool 3 37, 24, 18 
Pool 4 24, 6, 36 Pool 4 23, 11, 41 Pool 4 27, 25, 5 Pool 4 39, 32, 33 
Pool 5 30, 22, 33 Pool 5 7, 24, 48 Pool 5 11, 37, 9 Pool 5 36, 31, 2 
Pool 6 43, 27, 15 Pool 6 26, 31, 14 Pool 6 3, 31, 24 Pool 6 9, 43, 44 
Pool 7 48, 12, 40 Pool 7 28, 29, 6 Pool 7 46, 2, 13 Pool 7 28, 22, 17 
Pool 8 23, 45, 4 Pool 8 3, 22, 19 Pool 8 4, 34, 33 Pool 8 23, 16, 6 
Pool 9 37, 25, 39 Pool 9 20, 47, 15 Pool 9 10, 47, 45 Pool 9 48, 48, 13 
Pool 10 28, 9, 11 Pool 10 25, 30, 13 Pool 10 15, 19, 36 Pool 10 42, 40, 27 
Pool 11 19, 3, 1 Pool 11 42, 5, 38 Pool 11 16, 42, 23 Pool 11 3, 11, 29 
Pool 12 14, 16, 32 Pool 12 17, 34, 40 Pool 12 7, 21, 12 Pool 12 47, 10, 8 
Pool 13 8, 18, 41 Pool 13 36, 46, 32 Pool 13 18, 43, 1 Pool 13 15, 26, 25 
Pool 14 39, 47, 35 Pool 14 45, 10, 1 Pool 14 39, 30, 17 Pool 14 12, 7, 4 
Pool 15 7, 17, 46 Pool 15 39, 9, 2 Pool 15 22, 40, 8 Pool 15 5, 41, 21 
Pool 16 10, 26, 44 Pool 16 33, 16, 27 Pool 16 32, 6, 38 Pool 16 14, 20, 35 
 
Table 5-2: siRNA Knockdown Pools 
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To investigate the role of these 47 cell surface proteins and the Bcl-2 
control siRNA in melanoma cell phagocytosis, we transfected M21-GFP 
melanoma cells with the siRNA pools using 100 µM of each siRNA or 400 µM of 
a non-targeting control siRNA. 48 hours following transfection, we placed the 
transfected cells into a phagocytosis assay with or without CD47 blockade. We 
tested the pools of siRNAs in seven experiments, each with its own set of 
controls. Phagocytosis of Raji lymphoma cells was utilized as a positive control 
and was consistently within the reference range for the experiments shown in 
Chapter 3. While testing the second group of siRNAs, poor macrophage viability 
(98% cell death), severely affected our ability to quantify cell phagocytosis; these 
data were therefore not included in our final analysis. Knockdown of Bcl-2 failed 
to decrease melanoma cell viability in these assays as anticipated. However, 
melanoma cells are notoriously resistant to apoptosis [150], so it is possible that 
expression of other anti-apoptotic proteins, such as Bcl-xL or Bcl-w, prevented 
Bcl-2 knockdown from inducing melanoma cell death [160].   
Of the 54 pools evaluated, five appeared to slightly increase melanoma 
cell phagocytosis as compared to the non-targeting control siRNA (Figure 5-5). 
While other siRNA pools caused a statistically significant increase in 
phagocytosis, this increase was not clearly apparent on 2-dimensional flow 
cytometry dot plots, and the overall percent phagocytosis remained very low; so, 
based on previous data (Chapter 3), we do not believe this increase was 
therapeutically meaningful.  
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Figure 5-5: Identification of five candidate siRNA pools that increase melanoma cell 
phagocytosis. M21-GFP melanoma cells were transfected with siRNA pools containing 
100 µM of 4 different siRNAs or 400 µM of a non-targeting control siRNA. 48 hours post-
transfection, M21-GFP cells were co-cultured with J774 macrophages in the presence of 
control IgG4 or CV1-G4. Phagocytosis was quantified as the percent of F4/80+ J774 cells 
that engulfed CFSE+ tumor cells per total F4/80+ population. Data were normalized to the 
non-targeting control for each experiment. Bars show data from duplicate tests (mean ± 
SEM) for each pool. p=0.0226 (Group 1), p=0.6783 (Group 2), p<0.0001 (Group 3), 
p=0.0244 (Group 4), Two-way ANOVA.  
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To validate whether the siRNAs contained in the five identified pools 
(Table 5-3) increased melanoma cell phagocytosis, we repeated the 
transfections using the same experimental conditions. Upon repeat transfection, 
several of the siRNA pools caused a statistically significant increase in 
phagocytosis, but again, these increases were not readily apparent on 2-
dimensional flow cytometry dot plots and the overall percent phagocytosis 
remained very low (Figure 5-6). Therefore, we again concluded that the siRNA 
pools failed to increase melanoma cell phagocytosis compared to the non-
targeting control siRNA.    
 
 
Group	Number	 Genes	Targeted		 Assigned	Numbers	
Group	1	Pool	1	 ITGB3,	CD81,	CAV1	 34,	5,	42	
Group	1	Pool	5	 ITGA5,	MADCAM1,	ITGB1	 30,	22,	33	
Group	1	Pool	10	 ITGA3,	SELPG,	CDH1	 28,	9,	11	
Group	2	Pool	9	 BCAM,	MFGE8,	CLDN12	 20,	47,	15	
Group	2	Pool	12		 MCAM,	ITGB3,	LGALS1	 17,	34,	39	
 
 
 
 
 
 
 
Table 5-3: Repeated siRNA Knockdown Pools 
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Conclusions: In this chapter, we investigated whether a secreted or membrane-
bound anti-phagocytic factor was responsible for melanoma cell resistance to 
phagocytosis. We demonstrated that supernatant harvested from melanoma cells 
was not capable of inhibiting Raji cell phagocytosis. In addition, treatment of 
human melanoma cells with an inhibitor of secretion, Brefeldin A, failed to 
increase melanoma cell phagocytosis. These results indicate that a secreted 
factor is not responsible for mediating melanoma cell resistance to phagocytosis. 
To investigate whether melanoma cells express an uncharacterized, membrane-
bound “don’t eat me” signal, we designed an siRNA panel targeting 47 “don’t eat 
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Figure 5-6: siRNA mediated knockdown of candidate proteins does not 
enhance melanoma cell phagocytosis. M21-GFP melanoma cells were 
transfected with siRNA pools containing 100 µM of 4 different siRNAs or 400 µM 
of a non-targeting control siRNA. 48 hours post-transfection, M21-GFP cells were 
co-cultured with J774 macrophages in the presence of control IgG4 or CV1-G4. 
Phagocytosis was quantified as the percent of F4/80+ J774 cells that engulfed 
CFSE+ tumor cells per total F4/80+ population.  Bars show data from duplicate 
tests for each pool (mean ± SEM). p=0.027 by two-way ANOVA  
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me” candidate proteins. Despite efficient knockdown of these proteins, none of 
the siRNAs tested in this panel were capable of enhancing melanoma cell 
phagocytosis. Therefore, the 47 proteins tested are unlikely to act as anti-
phagocytic factors for melanoma cells. Further investigation will be needed to 
identify the mechanisms that mediate the peculiar resistance of melanoma cells 
to phagocytosis.  
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Classically activated macrophages have the potential to mediate robust 
anti-tumor immunity through phagocytic clearance of tumor cells and antigen 
presentation to the adaptive immune system [37].  Phagocytosis relies on a 
balance of pro-phagocytic (“eat me”) and anti-phagocytic (“don’t eat me”) signals 
expressed on the surface of target cells [48], which can be therapeutically altered 
to promote an anti-tumor innate immune response. Induction of “eat me” signals 
through anthracycline chemotherapy and blockade of the “don’t eat me” signal 
CD47 have been shown to stimulate phagocytosis of both hematopoietic and 
solid tumor cells in vitro and to induce anti-tumor immune responses in vivo 
[64,66,75,83]. Although CD47 blockade has been shown to induce tumor 
regression in a number of solid tumor models, including ovarian [66], breast 
[66,73], bladder [66], leiomyosarcoma [74], colon [75], pancreatic [76], and lung 
[77] cancers, the effect of targeting the CD47-SIRPa axis for the treatment of 
malignant melanoma was previously unclear. Macrophages containing 
phagocytosed tumor material have been visualized within mouse melanoma 
tumors [47], which suggests that macrophage-activating therapies may be 
efficacious in the treatment of this disease.  
Despite recent therapeutic advances, malignant melanoma remains the 
deadliest form of skin cancer with poor overall survival rates for patients with 
advanced, metastatic disease [3]. Immunotherapies targeting the adaptive 
immune system, including antibodies against the checkpoint molecules CTLA-4 
and PD-1, have led to complete, durable responses in a subset of malignant 
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melanoma patients. However, over 40% of patients fail to respond to combination 
checkpoint blockade, emphasizing the need to develop additional therapeutics 
for the treatment of this disease. Enhancing tumor cell phagocytosis and antigen 
presentation may lead to an improved anti-tumor immune response and promote 
durable remissions in the subset of advanced melanoma patients that display 
resistance to current treatment modalities.   
 In addition to the human disease, malignant melanoma occurs in a 
number of other species, such as dogs and mice. Mouse models of malignant 
melanoma have been traditionally used to study tumor growth and the interaction 
of tumor cells with the host immune system. These models are widely used due 
to the ability to manipulate the mouse genome and the ability to easily harvest 
tumors and immune organs for further study. However, few spontaneous mouse 
models of melanoma exist, and these models may fail to recapitulate the 
heterogeneity and complexity of human tumors [14].  
Canine malignant melanoma, which develops spontaneously in the setting 
of an intact immune system, represents another relevant translational model for 
human malignant melanoma (see Table 1-2). Unlike human malignant 
melanoma, canine malignant melanoma typically arises from pigment cells in the 
oral cavity, although it can also arise from dermal melanocytes. Despite 
differences in disease distribution and etiology, canine and human malignant 
melanoma share similar clinical presentations, histopathology, disease 
progression, and several molecular signaling pathways [22,25,26]. Similar to 
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human disease, loco-regional control of stage I/II canine melanoma can be 
achieved using radiation or surgery, but few efficacious treatments exist for 
advanced, metastatic disease, and the median overall survival for these patients 
remains poor [22]. The canine model provides the ability to perform preclinical 
trials in companion dogs that share similar environments to human patients [15]. 
Although murine and canine models have unique advantages and disadvantages 
(reviewed in Table 1-1), both models have the potential to significantly inform our 
understanding of human malignant melanoma. The collective knowledge gained 
from the use of these models can assist in the development of more efficacious 
therapies for patients with advanced disease [14].   
Our objective in this dissertation was to characterize the anti-tumor 
immune response following modulation of pro-phagocytic and anti-phagocytic 
signals in malignant melanoma. Advances in cancer immunotherapy depend on 
preclinical testing, which provides critical insights into therapeutic efficacy and 
mechanisms of action. In order to provide a framework for preclinical testing, it is 
important to understand the similarities and differences in melanoma cell biology 
between human, mouse, and canine tumors. Identifying similarities in tumors 
from multiple species could reveal mechanisms of immunoevasion that are likely 
to be important for tumor cell survival. However, human melanoma may have 
significant biological differences from mouse or canine melanoma, and 
awareness of these differences is important to avoid over interpretation of data 
gained from animal models. Therefore, in this study, we utilized a multi-species 
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approach to evaluate the response of human, mouse, and canine melanoma 
cells to modulation of phagocytic signals.  
Our first aim was to characterize the anti-tumor immune response to 
melanoma following CD47 blockade (Chapter 3). We confirmed the expression of 
CD47 on the surface of human, mouse, and dog melanoma cells and validated 
the ability of a SIRPa mimotope, CV1-G4, and an anti-CD47 monoclonal 
antibody, MIAP301, to block the CD47-SIRPa axis on these cells. Surprisingly, 
we found that melanoma cells from all three species displayed a resistance to 
phagocytosis that was not seen in lymphoma, breast/mammary gland cancer, or 
osteosarcoma cells, and the resistance of melanoma cells could not be fully 
mitigated by CD47 blockade. This defect in phagocytosis did not appear to be 
macrophage- or reagent-dependent, as similar results were seen with 
macrophages derived from two different sources and using different CD47 
blocking reagents.  
Next, we utilized a syngeneic mouse model of melanoma to evaluate the 
effect of CD47 blockade on anti-tumor T cell responses. CD47 blockade led to a 
slight increase in antigen-specific CD8+ T cell activation in the tumor draining 
lymph node. This response appeared to be tumor specific, as no change in T cell 
activation was observed in the contralateral (non-tumor draining) lymph node. 
However, the increase in CD8+ T cell activation did not appear to be 
therapeutically significant as CD47 blockade failed to mediate tumor regression 
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in this model. These results suggest that CD47 blockade, when used as single-
agent therapy, could not overcome melanoma cell resistance to phagocytosis or 
lead to an anti-tumor T cell response capable of mediating tumor regression.  
Although therapies targeting the CD47-SIRPa axis have demonstrated 
efficacy in a variety of hematopoietic and solid tumor types [64-66], previous 
studies have produced contradictory results regarding the efficacy of CD47 
blockade in the treatment of malignant melanoma. In agreement with our study, 
Sockolosky et al [85] examined the effects of CD47 blockade in a B16 mouse 
model of melanoma and demonstrated no increase in tumor cell phagocytosis 
and no inhibition of tumor growth following treatment with an anti-mouse CD47 
nanobody. However, Ngo et al [88] used an anti-CD47 antibody for the treatment 
of primary human melanoma xenografts and demonstrated an increase in 
melanoma cell phagocytosis in vitro as well as a decrease in tumor growth and 
metastasis in vivo following CD47 blockade. Our work provides a systematic 
evaluation of melanoma cell phagocytosis by examining the effects of CD47 
blockade on melanoma cells derived from human, mouse, and dog cells. Similar 
to the study by Ngo, we observed a small increase in melanoma cell 
phagocytosis in vitro. However, our work revealed that the overall levels of 
melanoma cell phagocytosis remained very low compared to lymphoma, 
breast/mammary gland cancer, and osteosarcoma cell phagocytosis. We 
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concluded that CD47 blockade alone could not fully mitigate melanoma cell 
resistance to phagocytosis. 
In our model, the small increase in melanoma cell phagocytosis following 
CD47 blockade did not appear to be therapeutically significant, as CD47 
blockade failed to decrease tumor growth in vivo, in agreement with Sockolosky 
et al [85], but contrary to Ngo [88], who demonstrated decreased tumor volume 
following CD47 blockade. These different sets of results could be explained by 
the unique features of the model systems used: Ngo used human melanoma 
tumors xenografted into immunodeficient mice, whereas here, we used a 
syngeneic model of mouse melanoma. In a xenograft model, only tumor cells 
express human CD47 and are capable of binding human CD47-targeting 
reagents. Therefore, xenograft models might achieve higher concentrations of 
anti-CD47 antibodies in the tumor than syngeneic models, in which both 
malignant and normal cells are capable of binding CD47, causing much of the 
antibody to be lost to a large “antigen sink.” Therefore, melanoma cells in an 
immunodeficient model may be cleared more easily than the syngeneic tumor 
cells used in our model system. Preclinical studies in cynomolgus macaques 
have also demonstrated the existence of a large antigen sink from CD47 
expressed on circulating red and white blood cells [67], which indicates that our 
syngeneic model might more accurately reflect a clinical setting.  
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Treatment with anthracycline chemotherapy has previously been shown to 
increase the expression of “eat me” signals and enhance tumor cell phagocytosis 
[53]. However, the effect of combining chemotherapy with CD47 blockade has 
yet to be examined. Our second goal was to evaluate whether increasing pro-
phagocytic signals in combination with CD47 blockade could enhance melanoma 
cell phagocytosis and activation of a tumor-specific T cell response (Chapter 4). 
We demonstrated that low-dose doxorubicin chemotherapy was capable of 
upregulating expression of the pro-phagocytic signals calreticulin and 
phosphatidylserine on the surface of mouse melanoma cells. Despite this 
increase, combination doxorubicin and CD47 blockade failed to increase 
melanoma cell phagocytosis in vitro. Combination chemo-immunotherapy also 
failed to enhance antigen-specific T cell activation in vitro and in vivo.  
In addition to increasing pro-phagocytic signals through low-dose 
chemotherapy, we utilized a tumor-specific antibody targeting the melanoma 
antigen CD271 to provide a pro-phagocytic signal through the Fc receptor. 
Combination CD271 and CD47 antibody therapy, again, failed to enhance 
melanoma cell phagocytosis. We concluded that melanoma cell resistance to 
phagocytosis could not be mitigated by modulation of know pro-phagocytic and 
anti-phagocytic signals.  
Having demonstrated that melanoma cells exhibit a unique resistance to 
phagocytosis, we hypothesized that this resistance was mediated by a soluble or 
  
122 
membrane-bound “don’t eat me” signal expressed by melanoma cells. We 
demonstrated that phagocytosis of melanoma cells was not enhanced by 
inhibition of secretory pathways using Brefeldin A, and phagocytosis of sensitive 
tumor cells (lymphoma) was not impaired in the presence of melanoma culture 
supernatants. Therefore, we concluded that secreted factors were not 
responsible for mediating melanoma cell resistance to phagocytosis. 
To investigate whether melanoma cells expressed an uncharacterized, 
membrane-bound “don’t eat me” signal that was responsible for the observed 
resistance to phagocytosis, we designed a siRNA panel targeting 47 “don’t eat 
me” candidate proteins. Proteins were selected using gene expression data and 
published reports in the scientific literature to identify candidate proteins that 
were selectively expressed on the surface of melanoma cells as compared to 
lymphoma, colon cancer, lung cancer, or breast cancer cells. None of the 47 
siRNAs tested in this panel were capable of enhancing melanoma cell 
phagocytosis following transfection. It is possible that we did not achieve 
sufficient protein knockdown using siRNAs to observe a change in cell 
phagocytosis. However, siRNA treatment achieved a 75-90% reduction in mRNA 
expression in eight genes selected for testing, and a CD47-targeting siRNA 
achieving similar levels of knockdown has been shown to increase the 
phagocytosis of laryngeal squamous cell carcinoma cells in vitro [161]. 
Therefore, we believe the siRNAs used in this study achieved adequate levels of 
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protein reduction, and we concluded that the 47 proteins tested are unlikely to act 
as anti-phagocytic factors for melanoma cells. 
A number of untested elements may be responsible for melanoma cell 
resistance to phagocytosis. It is possible that an untested membrane-bound 
protein is responsible for inhibiting melanoma cell phagocytosis. A genome wide 
screen could be used to identify this protein; however, if the protein responsible 
for mediating resistance were stably expressed (and therefore unaffected by a 
knockout screen), it would not be detected in this assay. It is also possible that a 
combination of proteins contributes to the resistant phenotype. Such 
combinations would not be detected by a genome wide screen, and testing the 
millions of possible protein combinations using genomic screens would be 
impractical. Although no carbohydrate or lipid-based “don’t eat me” signals have 
been identified to date, non-protein elements of melanoma cells have the 
potential to transmit anti-phagocytic signals. Assays to reduce cell glycosylation 
could be performed to test for the presence of a carbohydrate moiety or a 
glycosylation pattern that is acting as “don’t eat me” signal. In addition, signaling 
through ceramide, sphingosine, and other membrane-bound lipids could mediate 
resistance to phagocytosis. Pharmacologic inhibitors of sphingolipid synthesis 
have been described and could be used to reduce sphingolipid expression in 
melanoma cells; however, many of these inhibitors have off-target effects on 
other molecules, which could make data interpretation challenging [162].    
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In this study, we observed a unique phagocytosis resistance phenotype in 
malignant melanoma cells. Evasion of phagocytosis and the innate immune 
response could be an important component of the primary resistance to 
immunotherapy seen in many melanoma patients. Thus, advancing our 
understanding of how melanoma cells avoid elimination by the innate immune 
system could lead to the development of new therapeutic strategies to improve 
patient responses and overcome immunotherapy resistance.  Further 
investigation will be needed to identify the mechanisms that mediate the peculiar 
resistance of melanoma cells to phagocytosis.   
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